Cigna (CI) 10-Q 6 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-38769
Entity Registrant Name	Cigna Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4991898
Entity Address, Address Line One	900 Cottage Grove Road
Entity Address, City or Town	Bloomfield
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06002
City Area Code	860
Local Phone Number	226-6000
Title of 12(b) Security	Common Stock, Par Value $0.01
Trading Symbol	CI
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		317,273,452
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001739940

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues
Premiums	$ 10,356	$ 10,214
Net investment income	414	391
TOTAL REVENUES	44,005	40,971
Benefits and expenses
Pharmacy and other service costs	29,813	27,235
Medical costs and other benefit expenses	8,268	8,005
Selling, general and administrative expenses	3,299	3,279
Amortization of acquired intangible assets	458	495
TOTAL BENEFITS AND EXPENSES	41,838	39,014
Income from operations	2,167	1,957
Interest expense and other	(299)	(314)
Debt extinguishment costs	0	(131)
Net realized investment gains (losses)	(319)	1
Income before income taxes	1,549	1,513
TOTAL INCOME TAXES	351	342
Net income	1,198	1,171
Less: Net income attributable to noncontrolling interests	15	10
SHAREHOLDERS' NET INCOME	$ 1,183	$ 1,161
Shareholders' net income per share
Basic (in dollars per share)	$ 3.71	$ 3.33
Diluted (in dollars per share)	$ 3.68	$ 3.30
Pharmacy revenues
Revenues
Revenues	$ 30,697	$ 28,025
Fees and other revenues
Revenues
Revenues	$ 2,538	$ 2,341

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 1,198	$ 1,171
Other comprehensive income (loss), net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(560)	(273)
Net translation gains (losses) on foreign currencies	(63)	(119)
Postretirement benefits liability adjustment	13	18
Other comprehensive (loss), net of tax	(610)	(374)
Total comprehensive income	588	797
Comprehensive income (loss) attributable to noncontrolling interests
Net income attributable to redeemable noncontrolling interests	3	5
Net income attributable to other noncontrolling interests	12	5
Other comprehensive (loss) attributable to redeemable noncontrolling interests	(2)	(4)
Total comprehensive income attributable to noncontrolling interests	13	6
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 575	$ 791

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 4,424	$ 5,081
Investments		731	920
Accounts receivable, net		16,003	15,071
Inventories		3,500	3,722
Other current assets		1,042	1,283
Assets of businesses held for sale		9,693	10,057
Total current assets		35,393	36,134
Long-term investments		17,693	18,438
Reinsurance recoverables		4,937	4,970
Deferred policy acquisition costs		719	677
Property and equipment		3,661	3,692
Goodwill		45,804	45,811
Other intangible assets		33,714	34,102
Other assets		2,541	2,728
Separate account assets		8,148	8,337
TOTAL ASSETS		152,610	154,889
Liabilities
Current insurance and contractholder liabilities		5,673	5,318
Pharmacy and other service costs payable		15,235	15,309
Accounts payable		6,632	6,655
Accrued expenses and other liabilities		7,833	7,322
Short-term debt		2,173	2,545
Liabilities of businesses held for sale		6,116	6,423
Total current liabilities		43,662	43,572
Non-current insurance and contractholder liabilities		12,167	12,563
Deferred tax liabilities, net		8,110	8,346
Other non-current liabilities		3,346	3,762
Long-term debt		31,013	31,125
Separate account liabilities		8,148	8,337
TOTAL LIABILITIES		106,446	107,705
Contingencies — Note 18
Redeemable noncontrolling interests		55	54
Shareholders' equity
Common stock	[1]	4	4
Additional paid-in capital		29,736	29,574
Accumulated other comprehensive loss		(1,492)	(884)
Retained earnings		33,420	32,593
Less: Treasury stock, at cost		(15,581)	(14,175)
TOTAL SHAREHOLDERS' EQUITY		46,087	47,112
Other noncontrolling interests		22	18
Total equity		46,109	47,130
Total liabilities and equity		$ 152,610	$ 154,889
[1]	Par value per share, $0.01; shares issued, 396 million as of March 31, 2022 and 394 million as of December 31, 2021; authorized shares, 600 million.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	396,000,000	394,000,000
Common stock, shares authorized (in shares)	600,000,000	600,000,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions	Total	Shareholders’ Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2020	$ 50,328	$ 50,321	$ 4	$ 28,975	$ (861)	$ 28,575	$ (6,372)	$ 7
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	192	192		279			(87)
Other comprehensive income (loss)	(370)	(370)			(370)
Net income	1,166	1,161				1,161		5
Common dividends declared	(347)	(347)				(347)
Repurchase of common stock	(2,808)	(2,808)					(2,808)
Other transactions impacting noncontrolling interests	(6)							(6)
Balance at Mar. 31, 2021	48,155	48,149	4	29,254	(1,231)	29,389	(9,267)	6
Balance at Dec. 31, 2020	58
Change in Redeemable Noncontrolling Interests
Other comprehensive (loss)	(4)
Net income	5
Other transactions impacting noncontrolling interests	0
Balance at Mar. 31, 2021	59
Balance at Dec. 31, 2021	47,130	47,112	4	29,574	(884)	32,593	(14,175)	18
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	90	90		162			(72)
Other comprehensive income (loss)	(608)	(608)			(608)
Net income	1,195	1,183				1,183		12
Common dividends declared	(356)	(356)				(356)
Repurchase of common stock	(1,334)	(1,334)					(1,334)
Other transactions impacting noncontrolling interests	(8)	0		0				(8)
Balance at Mar. 31, 2022	46,109	$ 46,087	$ 4	$ 29,736	$ (1,492)	$ 33,420	$ (15,581)	$ 22
Balance at Dec. 31, 2021	54
Change in Redeemable Noncontrolling Interests
Other comprehensive (loss)	(2)
Net income	3
Other transactions impacting noncontrolling interests	0
Balance at Mar. 31, 2022	$ 55

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 1.12	$ 1	$ 1	$ 1	$ 1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities
Net income		$ 1,198	$ 1,171
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		717	715
Realized investment (gains) losses, net		319	(1)
Deferred income tax (benefit)		(138)	(35)
Debt extinguishment costs		0	131
Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable		(983)	(1,420)
Inventories		222	247
Deferred policy acquisition costs		(41)	(60)
Reinsurance recoverable and Other assets		443	40
Insurance liabilities		396	443
Pharmacy and other service costs payable		(74)	415
Accounts payable and Accrued expenses and other liabilities		34	(637)
Other, net		(63)	84
NET CASH PROVIDED BY OPERATING ACTIVITIES		2,030	1,093
Proceeds from investments sold:
Debt securities and equity securities		757	378
Investment maturities and repayments:
Debt securities and equity securities		456	328
Commercial mortgage loans		65	72
Other sales, maturities and repayments (primarily short-term and other long-term investments)		479	364
Investments purchased or originated:
Debt securities and equity securities		(1,246)	(980)
Commercial mortgage loans		(59)	0
Other (primarily short-term and other long-term investments)		(425)	(637)
Property and equipment purchases, net		(288)	(242)
Divestiture, net of cash sold		(57)	0
Other, net		(6)	0
NET CASH (USED IN) INVESTING ACTIVITIES		(324)	(717)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds		43	47
Withdrawals and benefit payments from contractholder deposit funds		(49)	(35)
Net change in short-term debt		(463)	(1,030)
Payments for debt extinguishment		0	(126)
Repayment of long-term debt		0	(4,199)
Net proceeds on issuance of long-term debt		0	4,262
Repurchase of common stock		(1,368)	(2,794)
Issuance of common stock		93	204
Common stock dividend paid		(357)	(345)
Other, net		(70)	(35)
NET CASH (USED IN) FINANCING ACTIVITIES		(2,171)	(4,051)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash		(23)	(26)
Net (decrease) in cash, cash equivalents and restricted cash		(488)	(3,701)
Cash, cash equivalents and restricted cash January 1,	[1]	5,548	10,245
Cash, cash equivalents and restricted cash, March 31,		5,060	6,544
Cash and cash equivalents reclassified to Assets of businesses held for sale		(591)	0
Total cash, cash equivalents and restricted cash and cash equivalents	[2]	4,469	6,544
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds		43	122
Interest paid		$ 308	$ 331
[1]	Includes $425 million reported in Assets of businesses held for sale as of January 1, 2022.
[2]	Restricted cash and cash equivalents were reported in Other long-term investments as of March 31, 2022 and March 31, 2021.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Statement of Cash Flows [Abstract]
Cash and cash equivalents reclassified to Assets of businesses held for sale	$ 591	$ 425	$ 0

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as "Cigna," the "Company," "we," "our" or "us") is a global health services organization with a mission of helping those we serve improve their health, well-being and peace of mind by making health care affordable, predictable and simple. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and supplemental products and services. The majority of these products are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these ongoing operations, Cigna also has certain run-off operations. Details of the Company's reporting segments and recent changes are provided below: We entered into a definitive agreement in October 2021 to sell our life, accident and supplemental benefits businesses in several countries to Chubb INA Holdings, Inc. ("Chubb"). As of March 31, 2022, we now expect to sell our life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for $5.72 billion in cash (the "Chubb Transaction"); we no longer expect to sell our interest in a joint venture in Turkey as part of the Chubb Transaction. See Note 5 for further information on the classification of these businesses as held for sale. In connection with the pending Chubb Transaction, we revised our business reporting structure. As such, we adjusted our segment reporting effective in the fourth quarter of 2021 and segment results for the three months ended March 31, 2021 have been restated to conform to the new segment presentation (see Note 19). A full description of our segments follows: Evernorth includes a broad range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy solutions, benefits management solutions, care delivery and care management solutions and intelligence solutions, which are provided to health plans, employers, government organizations and health care providers. Cigna Healthcare includes U.S. Commercial, U.S. Government and International Health operating segments that provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and self-insured customers. U.S. Government solutions include Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans both on and off the public exchanges. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. Other Operations contains the remainder of our business operations, consisting of the following: • Ongoing business: • Corporate-Owned Life Insurance ("COLI") offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for the purpose of financing employer-paid future benefit obligations. • Our interest in a joint venture in Turkey. • Exiting businesses: • International Life, Accident and Supplemental Benefits Businesses in six countries to be sold pursuant to the Chubb Transaction. • Run-off businesses: • Reinsurance: predominantly comprised of guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013. • Settlement Annuity and other businesses in run-off. • Individual Life Insurance and Annuity and Retirement Benefits businesses: deferred gains from the sales of these businesses. Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, severance, certain overhead and enterprise-wide project costs and intersegment eliminations for products and services sold between segments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment. There were no new accounting standards adopted as of March 31, 2022 that had a material impact on our financial statements. There are no accounting pronouncements not yet adopted, with the exception of Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Insurance Contracts

Accounts Receivable, Net

Accounts Receivable, Net	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Accounts Receivable, Net	Note 3 – Accounts Receivable, Net The following amounts were included within Accounts receivable, net: (In millions) March 31, 2022 December 31, 2021 Noninsurance customer receivables $ 7,200 $ 6,274 Pharmaceutical manufacturers receivables 5,805 5,463 Insurance customer receivables 2,647 2,932 Other receivables 399 456 Total 16,051 15,125 Accounts receivable, net classified as Assets of businesses held for sale (48) (54) Accounts receivable, net per Consolidated Balance Sheets $ 16,003 $ 15,071

Mergers, Acquisitions and Dives

Mergers, Acquisitions and Divestitures	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Mergers, Acquisitions and Divestitures	Note 4 – Mergers, Acquisitions and Divestitures A. Acquisition of MDLIVE On April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. ("MDLIVE"), a 24/7 virtual care platform. Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE. The Company's 2021 Form 10-K includes detailed disclosures of merger consideration, purchase price allocation and intangible assets identified in this transaction. In accordance with GAAP, the total consideration transferred has been allocated to the tangible and intangible net assets acquired based on management's estimates of their fair values and is now finalized as of March 31, 2022. For the three months ended March 31, 2022, there were immaterial changes to the purchase price allocation.

Assets and Liabilities of Busin

Assets and Liabilities of Businesses Held for Sale	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Business Held for Sale	Note 5 – Assets and Liabilities of Businesses Held for Sale We entered into a definitive agreement in October 2021 to sell our life, accident and supplemental benefits businesses in several countries to Chubb. As of March 31, 2022, we now expect to sell our life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for $5.72 billion in cash. Subject to applicable regulatory approvals and customary closing conditions, we expect to complete the sale of these businesses in the second quarter of 2022. The Company has aggregated and classified the assets and liabilities of these businesses as held for sale in our Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021. The assets and liabilities of our interest in a joint venture in Turkey were classified as held for sale in our Consolidated Balance Sheet as of December 31, 2021; however, we no longer expect to sell this business to Chubb and the assets and liabilities are no longer classified as held for sale. The assets and liabilities of businesses held for sale were as follows: (In millions) March 31, 2022 December 31, 2021 Cash and cash equivalents $ 591 $ 406 Investments 4,771 5,109 Deferred policy acquisition costs 2,717 2,755 Separate account assets 718 878 Goodwill, other intangible assets and all other assets 896 909 Total assets of businesses held for sale 9,693 10,057 Insurance and contractholder liabilities 4,562 4,644 Accounts payable, accrued expenses and other liabilities 436 452 Deferred tax liabilities, net 400 449 Separate account liabilities 718 878 Total liabilities of businesses held for sale $ 6,116 $ 6,423

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 6 – Earnings Per Share ("EPS")Basic and diluted earnings per share were computed as follows: Three Months Ended March 31, 2022 March 31, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 1,183 $ 1,183 $ 1,161 $ 1,161 Shares: Weighted average 318,487 318,487 348,248 348,248 Common stock equivalents 2,795 2,795 3,728 3,728 Total shares 318,487 2,795 321,282 348,248 3,728 351,976 EPS $ 3.71 $ (0.03) $ 3.68 $ 3.33 $ (0.03) $ 3.30 Three Months Ended March 31, (In millions) 2022 2021 Anti-dilutive options 2.8 1.5

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 7 – Debt The outstanding amounts of debt and finance leases were as follows: (In millions) March 31, 2022 December 31, 2021 Short-term debt Commercial paper $ 1,570 $ 2,027 $500 million, 3.05% Notes due 11/2022 496 495 $17 million, 8.3% Notes due 1/2023 17 — $63 million, 7.65% Notes due 3/2023 63 — Other, including finance leases 27 23 Total short-term debt $ 2,173 $ 2,545 Long-term debt $17 million, 8.3% Notes due 2023 $ — $ 17 $63 million, 7.65% Notes due 2023 — 63 $700 million, Floating Rate Notes due 2023 699 699 $1,000 million, 3% Notes due 2023 987 985 $1,187 million, 3.75% Notes due 2023 1,185 1,185 $500 million, 0.613% Notes due 2024 499 498 $1,000 million, 3.5% Notes due 2024 985 983 $900 million, 3.25% Notes due 2025 897 897 $2,200 million, 4.125% Notes due 2025 2,193 2,193 $1,500 million, 4.5% Notes due 2026 1,504 1,504 $800 million, 1.25% Notes due 2026 797 796 $1,500 million, 3.4% Notes due 2027 1,426 1,423 $259 million, 7.875% Debentures due 2027 259 259 $600 million, 3.05% Notes due 2027 596 596 $3,800 million, 4.375% Notes due 2028 3,783 3,782 $1,500 million, 2.4% Notes due 2030 1,491 1,490 $1,500 million, 2.375% Notes due 2031 (1) 1,448 1,500 $45 million, 8.3% Step Down Notes due 2033 45 45 $190 million, 6.15% Notes due 2036 190 190 $2,200 million, 4.8% Notes due 2038 2,192 2,192 $750 million, 3.2% Notes due 2040 743 743 $121 million, 5.875% Notes due 2041 119 119 $448 million, 6.125% Notes due 2041 488 490 $317 million, 5.375% Notes due 2042 315 315 $1,500 million, 4.8% Notes due 2046 1,465 1,465 $1,000 million, 3.875% Notes due 2047 989 988 $3,000 million, 4.9% Notes due 2048 2,968 2,967 $1,250 million, 3.4% Notes due 2050 1,236 1,236 $1,500 million, 3.4% Notes due 2051 1,477 1,477 Other, including finance leases 37 28 Total long-term debt $ 31,013 $ 31,125 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 for further information about the Company's interest rate risk management and these derivative instruments. Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of March 31, 2022, Cigna had a $3.0 billion five-year revolving credit and letter of credit agreement maturing in April 2026; a $1.0 billion three-year revolving credit agreement maturing in April 2024; and a $1.0 billion 364-day revolving credit agreement maturing in April 2022. There were no outstanding balances under these revolving credit agreements as of March 31, 2022. In April 2022, Cigna entered into the following revolving credit agreements ("Credit Agreements"), which replaced the agreements discussed above: • a $3.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2027 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. Cigna can borrow up to $3.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. • a $1.0 billion three-year revolving credit agreement that will mature in April 2025 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. Cigna can borrow up to $1.0 billion under the credit agreement for general corporate purposes. • a $1.0 billion 364-day revolving credit agreement that will mature in April 2023. Cigna can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion. Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across all three facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term secured overnight funding rate ("SOFR") plus, in each case, an applicable margin based on Cigna's senior unsecured credit ratings. Each of the three facilities is diversified among 22 banks. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition. Commercial Paper. Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper average interest rate was 0.60% at March 31, 2022. The Company was in compliance with its debt covenants as of March 31, 2022.

Common and Preferred Stock

Common and Preferred Stock	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Common and Preferred Stock	Note 8 – Common and Preferred Stock Dividends In the first quarter of 2022, Cigna declared and paid a quarterly cash dividend of $1.12 per share of Cigna common stock. In 2021, Cigna initiated and declared quarterly cash dividends of $1.00 per share of Cigna common stock. The following table provides details of Cigna's dividend payments for the three months ended March 31: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2022 March 9, 2022 March 24, 2022 $1.12 $357 2021 March 10, 2021 March 25, 2021 $1.00 $345 On April 27, 2022, the Board of Directors declared the second quarter cash dividend of $1.12 per share of Cigna common stock to be paid on June 23, 2022 to shareholders of record on June 8, 2022. Cigna currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of Cigna and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

Insurance and Contractholder Li

Insurance and Contractholder Liabilities	3 Months Ended
	Mar. 31, 2022
Insurance Loss Reserves [Abstract]
Insurance and Contractholder Liabilities	Note 9 – Insurance and Contractholder Liabilities A. Account Balances – Insurance and Contractholder Liabilities The Company's insurance and contractholder liabilities were comprised of the following: March 31, 2022 December 31, 2021 March 31, 2021 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 368 $ 6,641 $ 7,009 $ 352 $ 6,702 $ 7,054 $ 7,161 Future policy benefits 237 8,896 9,133 312 9,194 9,506 9,306 Unearned premiums 619 416 1,035 558 418 976 950 Unpaid claims and claim expenses Cigna Healthcare 4,459 32 4,491 4,159 102 4,261 4,027 Other Operations 503 231 734 548 180 728 723 Total 6,186 16,216 22,402 5,929 16,596 22,525 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (513) (4,049) (4,562) (611) (4,033) (4,644) Total insurance and contractholder liabilities $ 5,673 $ 12,167 $ 17,840 $ 5,318 $ 12,563 $ 17,881 $ 22,167 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.7 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of March 31, 2022 and $3.8 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of December 31, 2021. Insurance and contractholder liabilities expected to be paid within one year are classified as current. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment for the three months ended March 31 was as follows: Three Months Ended (In millions) March 31, 2022 March 31, 2021 Beginning balance $ 4,261 $ 3,695 Less: Reinsurance and other amounts recoverable 261 237 Beginning balance, net 4,000 3,458 Incurred costs related to: Current year 8,024 7,755 Prior years (276) (233) Total incurred 7,748 7,522 Paid costs related to: Current year 4,634 4,640 Prior years 2,822 2,555 Total paid 7,456 7,195 Ending balance, net 4,292 3,785 Add: Reinsurance and other amounts recoverable 199 242 Ending balance $ 4,491 $ 4,027 Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 for additional information on reinsurance. Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions for the three months ended March 31 were as follows: Three Months Ended (Dollars in millions) March 31, 2022 March 31, 2021 $ % (1) $ % (2) Actual completion factors $ 99 0.3 % $ 107 0.4 % Medical cost trend 177 0.6 126 0.4 Total favorable variance $ 276 0.9 % $ 233 0.8 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2021. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2020. Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions. Liability balance details. The liability details for unpaid claims and claim expenses are as follows. The liability balance no longer includes the International Health businesses now reported in Cigna Healthcare following our change in segment reporting. The prior year roll forward has been updated to reflect the segment change. (In millions) March 31, 2022 March 31, 2021 Other Operations International businesses to be sold and our interest in a joint venture in Turkey $ 436 $ 442 Other Operations 298 281 Unpaid claims and claim expenses Other Operations $ 734 $ 723 Activity in the unpaid claims and claim expenses for international businesses held for sale and our interest in a joint venture in Turkey is presented in the following table. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been largely reinsured. Three Months Ended (In millions) March 31, 2022 (1) March 31, 2021 Beginning balance $ 447 $ 452 Less: Reinsurance 46 45 Beginning balance, net 401 407 Incurred claims related to: Current year 259 254 Prior years (7) — Total incurred 252 254 Paid claims related to: Current year 116 115 Prior years 135 134 Total paid 251 249 Foreign currency (6) (15) Ending balance, net 396 397 Add: Reinsurance 40 45 Ending balance $ 436 $ 442 (1) Includes unpaid claims amounts classified as Liabilities of businesses held for sale. Reinsurance in the table above reflects amounts due from reinsurers related to unpaid claims liabilities. See Note 10 for additional information on reinsurance.

Reinsurance

Reinsurance	3 Months Ended
	Mar. 31, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	Note 10 – Reinsurance The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables. The Company's reinsurance recoverables as of March 31, 2022 are presented in the following table by range of external credit rating and collateral level: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 176 $ 176 BBB- to BBB+ equivalent current credit ratings (1) — — 61 61 Not rated 116 — 43 159 Total recoverables related to ongoing operations (2) 116 — 280 396 Acquisition, disposition or run-off activities A- equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,908 — 2,908 Berkshire Hathaway Life Insurance Company of Nebraska 268 376 — 644 Prudential Retirement Insurance and Annuity 149 — — 149 Prudential Insurance Company of America 404 — — 404 Life Insurance Company of North America — 437 — 437 Other 219 16 16 251 Not rated — 13 3 16 Total recoverables related to acquisition, disposition or run-off activities 1,040 3,750 19 4,809 Total $ 1,156 $ 3,750 $ 299 $ 5,205 Allowance for uncollectible reinsurance (30) Total reinsurance recoverables (2) $ 5,175 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $143 million of current reinsurance recoverables that are reported in Other current assets and $95 million of recoverables classified as Assets of businesses held for sale as of March 31, 2022. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value. The Company entered into an agreement with Berkshire to effectively exit the GMDB and GMIB business via a reinsurance transaction in 2013. Berkshire reinsured 100% of the Company's future claim payments in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.2 billion remaining at March 31, 2022. GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2021 Form 10-K. GMDB The GMDB exposure arises under annuities written by ceding companies that guarantee the benefit received at death. The Company's exposure arises when the guaranteed minimum death benefit exceeds the fair value of the related mutual fund investments at the time of a contractholder's death. The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) March 31, 2022 December 31, 2021 Account value $ 9,057 $ 9,795 Net amount at risk $ 1,508 $ 1,392 Number of contractholders (estimated) 165,000 170,000 GMIB The Company reinsured contracts with issuers of GMIB products. The Company's exposure represents the excess of a contractually guaranteed amount over the level of variable annuity account values. Payment by the Company depends on the actual account value in the related underlying mutual funds and the level of interest rates when the contractholders elect to receive minimum income payments that can only occur within 30 days of a policy anniversary after the appropriate waiting period. The Company has purchased retrocessional coverage ("GMIB assets") for these contracts including retrocessional coverage from Berkshire. GMIB liabilities totaling $514 million as of March 31, 2022 and $572 million as of December 31, 2021 are classified as Level 3 because fair value inputs are largely unobservable. The GMIB liabilities reflect the Company's credit risk, while the reinsurance recoverable reflects the credit risk of the reinsurers. There were three reinsurers covering 100% of the GMIB exposures as of March 31, 2022 and December 31, 2021 as follows: (In millions) Line of Business Reinsurer March 31, 2022 December 31, 2021 Collateral and Other Terms at March 31, 2022 GMIB Berkshire $ 257 $ 283 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 151 167 Liberty Re (Bermuda) Ltd. 138 151 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 546 $ 601 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments

Investments	3 Months Ended
	Mar. 31, 2022
Investments [Abstract]
Investments	Note 11 – Investments Cigna's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 12 for information about the valuation of the Company's investment portfolio. Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2021 Form 10-K. The following table summarizes the Company's investments by category and current or long-term classification: March 31, 2022 December 31, 2021 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 803 $ 14,611 $ 15,414 $ 796 $ 16,162 $ 16,958 Equity securities 50 821 871 — 603 603 Commercial mortgage loans 13 1,546 1,559 40 1,526 1,566 Policy loans — 1,316 1,316 — 1,338 1,338 Other long-term investments — 3,845 3,845 — 3,574 3,574 Short-term investments 190 — 190 428 — 428 Total 1,056 22,139 23,195 1,264 23,203 24,467 Investments classified as assets of businesses held for sale (1) (325) (4,446) (4,771) (344) (4,765) (5,109) Investments per Consolidated Balance Sheets $ 731 $ 17,693 $ 18,424 $ 920 $ 18,438 $ 19,358 (1) Investments related to the international life, accident and supplemental benefits businesses that are held for sale. These investments are primarily comprised of debt securities and other long-term investments, and to a lesser extent, equity securities and short-term investments. See Note 5 to the Consolidated Financial Statements for additional information. The amortized cost and fair value by contractual maturity periods for debt securities were as follows at March 31, 2022: (In millions) Amortized Fair Due in one year or less $ 796 $ 799 Due after one year through five years 4,978 4,948 Due after five years through ten years 4,967 4,859 Due after ten years 4,163 4,410 Mortgage and other asset-backed securities 413 398 Total $ 15,317 $ 15,414 Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties. Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair March 31, 2022 Federal government and agency $ 298 $ — $ 75 $ (4) $ 369 State and local government 158 — 4 (3) 159 Foreign government 2,467 — 142 (114) 2,495 Corporate 11,981 (23) 409 (374) 11,993 Mortgage and other asset-backed 413 — 4 (19) 398 Total $ 15,317 $ (23) $ 634 $ (514) $ 15,414 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,297 $ (5) $ 412 $ (52) $ 2,652 December 31, 2021 Federal government and agency $ 287 $ — $ 101 $ (1) $ 387 State and local government 154 — 17 — 171 Foreign government 2,468 — 194 (46) 2,616 Corporate 12,361 (23) 1,008 (80) 13,266 Mortgage and other asset-backed 505 — 17 (4) 518 Total $ 15,775 $ (23) $ 1,337 $ (131) $ 16,958 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,262 $ (5) $ 720 $ (10) $ 2,967 (1) Net unrealized appreciation for these investments is excluded from Accumulated other comprehensive loss. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region. The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. These debt securities are primarily corporate securities with a decline in fair value that reflects an increase in market yields since purchase. Our allowance for credit losses on debt securities was not material as of March 31, 2022 and December 31, 2021. March 31, 2022 December 31, 2021 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 5,398 $ 5,730 $ (332) 1,761 $ 2,785 $ 2,861 $ (76) 909 Below investment grade 957 1,006 (49) 1,406 561 578 (17) 781 More than one year Investment grade 816 930 (114) 348 382 412 (30) 143 Below investment grade 226 245 (19) 137 162 170 (8) 53 Total $ 7,397 $ 7,911 $ (514) 3,652 $ 3,890 $ 4,021 $ (131) 1,886 Equity Securities The following table provides the values of the Company's equity security investments as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 840 $ 464 $ 257 $ 207 Equity securities with no readily determinable fair value 280 407 270 396 Total $ 1,120 $ 871 $ 527 $ 603 Approximately 65% of our investments in equity securities are in the health care sector, consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry. The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio as of March 31, 2022 and December 31, 2021: (Dollars in millions) March 31, 2022 December 31, 2021 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 555 2.21 $ 560 2.18 60% to 79% 882 1.89 883 1.89 80% to 100% 129 1.47 129 1.47 Allowance for credit losses (7) (6) Total $ 1,559 1.97 61 % $ 1,566 1.96 61 % All commercial mortgage loans in the Company's portfolio are current as of March 31, 2022 and December 31, 2021. Other Long-Term Investments Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments: Carrying value as of (In millions) March 31, 2022 December 31, 2021 Real estate investments $ 1,212 $ 1,152 Securities partnerships 2,463 2,272 Other 170 150 Total $ 3,845 $ 3,574 The gross fair values of our derivative financial instruments are presented in Note 12. As of March 31, 2022 and December 31, 2021, the effects of derivative financial instruments used in these individual hedging strategies were not material to the Consolidated Financial Statements, including gains or losses reclassified from Accumulated other comprehensive loss into Shareholders' net income, amounts excluded from the assessment of hedge effectiveness and fair values of assets posted or held as collateral supporting the fair values of these derivative financial instruments. The following table summarizes the types and notional quantity of derivative instruments held by the Company: Notional Value as of (In millions) March 31, 2022 December 31, 2021 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Foreign currency swap contracts $ 1,110 $ 1,081 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 750 $ 750 Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. Foreign currency swap contracts $ 526 $ 526 Foreign currency forward contracts $ 1,360 $ 1,380 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts $ 749 $ 720 The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended March 31, (In millions) 2022 2021 Net realized investment gains (losses), excluding credit loss expense and asset write-downs $ (319) $ 10 Credit loss (expense) recoveries — (9) Net realized investment gains (losses), before income taxes $ (319) $ 1

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 12 – Fair Value Measurements The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and The following table provides information as of March 31, 2022 and December 31, 2021 about the Company's financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to policyholders. (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of March 31, 2022 As of December 31, 2021 As of March 31, 2022 As of December 31, 2021 As of March 31, 2022 As of December 31, 2021 As of March 31, 2022 As of December 31, 2021 Financial assets at fair value Debt securities Federal government and agency $ 149 $ 147 $ 220 $ 240 $ — $ — $ 369 $ 387 State and local government — — 159 171 — — 159 171 Foreign government — — 2,490 2,611 5 5 2,495 2,616 Corporate — — 11,468 12,606 525 660 11,993 13,266 Mortgage and other asset-backed — — 273 418 125 100 398 518 Total debt securities 149 147 14,610 16,046 655 765 15,414 16,958 Equity securities (1) 12 16 421 160 31 31 464 207 Short-term investments — — 190 428 — — 190 428 Derivative assets — — 159 143 — — 159 143 Financial liabilities at fair value Derivative liabilities $ — $ — $ 29 $ 33 $ — $ — $ 29 $ 33 (1) Excludes certain equity securities that have no readily determinable fair value. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Quantitative Information about Unobservable Inputs The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of March 31, 2022 and December 31, 2021. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions ) March 31, 2022 December 31, 2021 Unobservable input March 31, 2022 March 31, 2022 December 31, 2021 Debt securities Corporate and government debt securities $ 529 $ 664 Liquidity 60 - 1200 (370) bps 60 - 1060 (410) bps Mortgage and other asset-backed securities 125 100 Liquidity 60 - 380 (130) bps 60 - 390 (100) bps Other debt securities 1 1 Total Level 3 debt securities $ 655 $ 765 A significant increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement. Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three months ended March 31, 2022 and 2021. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended (In millions) 2022 2021 Debt and Equity Securities Beginning balance $ 796 $ 854 Total gains (losses) included in shareholders' net income 12 (10) Gains (losses) included in other comprehensive income (15) (16) Gains (losses) required to adjust future policy benefits for settlement annuities (1) (12) (8) Purchases, sales and settlements Purchases 49 29 Settlements (81) (16) Total purchases, sales and settlements (32) 13 Transfers into/(out of) Level 3 Transfers into Level 3 101 86 Transfers out of Level 3 (164) (16) Total transfers into/(out of) Level 3 (63) 70 Ending balance $ 686 $ 903 Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date $ — $ (11) Change in unrealized gains or losses included in Other comprehensive (loss), net of tax for assets held at the end of the reporting period $ (13) $ (16) (1) Amounts do not accrue to shareholders. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive (loss), net of tax in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income. Separate Accounts The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fair values of Separate account assets at March 31, 2022 and December 31, 2021 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 Guaranteed separate accounts (See Note 18) $ 239 $ 227 $ 271 $ 276 $ — $ — $ 510 $ 503 Non-guaranteed separate accounts (1) 460 1,130 6,676 6,406 311 334 7,447 7,870 Subtotal $ 699 $ 1,357 $ 6,947 $ 6,682 $ 311 $ 334 7,957 8,373 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 909 842 Total 8,866 9,215 Separate account assets of businesses classified as held for sale (2) (718) (878) Separate account assets per Consolidated Balance Sheets $ 8,148 $ 8,337 (1) Non-guaranteed separate accounts include $4.4 billion as of March 31, 2022 and $4.5 billion as of December 31, 2021 in assets supporting the Company's pension plans, including $0.3 billion classified in Level 3 as of March 31, 2022 and December 31, 2021. (2) Investments related to the international life, accident and supplemental benefits businesses that are held for sale. See Note 5 to the Consolidated Financial Statements for additional information. . Separate account assets classified in Level 3 primarily support Cigna's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three months ended March 31, 2022 or 2021. Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of March 31, 2022 Redemption Frequency Redemption Notice (In millions) March 31, 2022 December 31, 2021 Securities partnerships $ 557 $ 513 $ 262 Not applicable Not applicable Real estate funds 348 325 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 909 $ 842 $ 262 As of March 31, 2022, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception. Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value. For the three months ended March 31, 2022 and 2021, no impairments were recognized requiring these assets to be measured at fair value. Realized investment gains and losses from these observable price changes for the three months ended March 31, 2022 and March 31, 2021 were not material. The following table includes the Company's financial instruments not recorded at fair value, however fair value disclosure is required at March 31, 2022 and December 31, 2021. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy March 31, 2022 December 31, 2021 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,519 $ 1,559 $ 1,598 $ 1,566 Long-term debt, including current maturities, excluding finance leases Level 2 $ 32,646 $ 31,552 $ 35,621 $ 31,593

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2022
Variable Interest Entities [Abstract]
Variable Interest Entities	Note 13 – Variable Interest EntitiesWe perform ongoing qualitative analyses of our involvement with variable interest entities to determine if consolidation is required. The Company determined that it was not a primary beneficiary in any material variable interest entity as of March 31, 2022 or December 31, 2021. The Company’s involvement with variable interest entities for which it is not the primary beneficiary has not changed materially from December 31, 2021. For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2021 Form 10-K. The Company has not provided, and does not intend to provide, financial support to any of these variable interest entities in excess of its maximum exposure.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 14 – Accumulated Other Comprehensive Income (Loss) ("AOCI") AOCI includes net unrealized appreciation (depreciation) on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (see Note 11), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized. Changes in the components of AOCI were as follows: Three Months Ended March 31, (In millions) 2022 2021 Securities and Derivatives Beginning balance $ 685 $ 900 (Depreciation) appreciation on securities and derivatives (705) (342) Tax benefit 154 65 Net (depreciation) appreciation on securities and derivatives (551) (277) Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses) (11) 5 Reclassification adjustment for tax expense (benefit) included in Shareholders' net income 2 (1) Net (gains) losses reclassified from AOCI to Shareholders' net income (9) 4 Other comprehensive (loss), net of tax (560) (273) Ending balance $ 125 $ 627 Translation of foreign currencies Beginning balance $ (233) $ (15) Translation of foreign currencies (60) (114) Tax (expense) (3) (5) Other comprehensive (loss), net of tax (63) (119) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests (2) (4) Shareholders' other comprehensive (loss), net of tax (61) (115) Ending balance $ (294) $ (130) Postretirement benefits liability Beginning balance $ (1,336) $ (1,746) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 16 20 Reclassification adjustment for settlement (Interest expense and other) — 3 Reclassification adjustment for tax (benefit) included in Shareholders' net income (3) (5) Net adjustments reclassified from AOCI to Shareholders' net income 13 18 Other comprehensive income, net of tax 13 18 Ending balance $ (1,323) $ (1,728)

Organizational Efficiency Plan

Organizational Efficiency Plan	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Organizational Efficiency Plan	Note 15 – Organizational Efficiency Plan During the fourth quarter of 2021, the Company approved a strategic plan to further leverage its ongoing growth to drive operational efficiency through enhancements to organizational structure and increased use of automation and shared services. As a result, during the fourth quarter of 2021, we recognized a charge in Selling, general and administrative expenses of $168 million, pre-tax ($119 million, after-tax) that included $59 million of one-time expenses related to abandonment of leased assets and impairment of property and equipment as well as $109 million of accrued expenses primarily for severance costs related to headcount reductions. We expect most of the severance to be paid by 2023. The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities: (In millions) Balance, December 31, 2021 $ 103 2022 payments (14) Balance, March, 31, 2022 $ 89

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Note 16 – Leases Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) March 31, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 456 $ 478 Accrued expenses and other liabilities $ 154 $ 159 Other non-current liabilities 407 436 Total operating lease liabilities $ 561 $ 595 Finance leases: Property and equipment, gross $ 118 $ 101 Accumulated depreciation (56) (51) Property and equipment, net $ 62 $ 50 Short-term debt $ 27 $ 23 Long-term debt 37 28 Total finance lease liabilities $ 64 $ 51 (1) Operating leases include $28 million as of March 31, 2022 and $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $25 million as of March 31, 2022, and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.
Leases	Note 16 – Leases Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) March 31, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 456 $ 478 Accrued expenses and other liabilities $ 154 $ 159 Other non-current liabilities 407 436 Total operating lease liabilities $ 561 $ 595 Finance leases: Property and equipment, gross $ 118 $ 101 Accumulated depreciation (56) (51) Property and equipment, net $ 62 $ 50 Short-term debt $ 27 $ 23 Long-term debt 37 28 Total finance lease liabilities $ 64 $ 51 (1) Operating leases include $28 million as of March 31, 2022 and $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $25 million as of March 31, 2022, and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 17 – Income TaxesIncome Tax ExpenseThe 22.7% effective tax rate for the three months ended March 31, 2022 was higher than the 22.6% rate for the same period in 2021. This increase is primarily attributable to an increase in state and foreign income taxes, partially offset by the favorable impact of the remeasurement of deferred income taxes.

Contingencies and Other Matters

Contingencies and Other Matters	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Note 18 – Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A. Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of March 31, 2022, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $430 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of March 31, 2022. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition. B. Certain Other Guarantees The Company had indemnification obligations as of March 31, 2022 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of March 31, 2022. C. Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the three months ended March 31, 2022. D. Legal and Regulatory Matters The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accruals for the matters discussed below under "Litigation Matters" and "Regulatory Matters" are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation. Litigation Matters Express Scripts Litigation with Anthem . In March 2016, Anthem filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Anthem also requested that the court enter declaratory judgment that Express Scripts is required to provide Anthem competitive benchmark pricing, that Anthem can terminate the agreement and that Express Scripts is required to provide Anthem with post-termination services at competitive benchmark pricing for one year following any termination by Anthem. Anthem claims it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Anthem and $150 million damages for service issues ("Anthem's Allegations"). On April 19, 2016, in response to Anthem's complaint, Express Scripts filed its answer denying Anthem's Allegations in their entirety and asserting affirmative defenses and counterclaims against Anthem. The court subsequently granted Anthem's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Anthem completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Anthem's pricing claims for damages totaling $14.8 billion and on most of Anthem's claims relating to service issues. Anthem's only remaining service claim relates to the review or processing of prior authorizations. Medicare Advantage. A qui tam action that was filed by a private individual on behalf of the government in the United States District Court for the Southern District of New York in 2017 was unsealed on August 6, 2020. The action asserts claims related to risk adjustment practices arising from certain health exams conducted as part of the Company's Medicare Advantage business. In September 2021, the qui tam action was transferred to the United States District Court for the Middle District of Tennessee. On January 11, 2022, the U.S. Department of Justice ("DOJ") (U.S. Attorney's Offices for the Southern District of New York and the Middle District of Tennessee) filed a motion to partially intervene, which is pending before the court. The Company has opposed the DOJ's motion to intervene and the government filed its reply brief on February 1, 2022. The motion has been fully briefed and is under the court's review. Regulatory Matters Civil Investigative Demand . The DOJ is conducting industry-wide investigations of Medicare Advantage organizations' risk adjustment practices. For certain Medicare Advantage organizations, including Cigna, those investigations have resulted in litigation (see "Litigation Matters—Medicare Advantage" above). The Company is currently responding to information requests (civil investigative demands) from the DOJ (U.S. Attorney's Office for the Eastern District of Pennsylvania). The Company is cooperating with the DOJ and has responded and continues to respond to its requests.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Note 19 – Segment Information See Note 1 for a description of our segments, including the segment change effective in the fourth quarter of 2021. Prior year segment information has been adjusted to reflect the segment change and a description of our basis of reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy related transactions between the Evernorth and Cigna Healthcare segments. The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income/loss attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance. The following tables present the special items recorded by the Company for the three months ended March 31, 2022 and 2021: Three Months Ended (In millions) March 31, 2022 March 31, 2021 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax Integration and transaction-related costs $ 37 $ 52 $ 22 $ 29 Debt extinguishment costs — — 101 131 (Benefits) charges associated with litigation matters — — (21) (27) Total impact from special items $ 37 $ 52 $ 102 $ 133 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2022 Revenues from external customers $ 32,289 $ 10,461 $ 841 $ — $ 43,591 Inter-segment revenues 1,287 562 — (1,849) Net investment income 10 266 138 — 414 Total revenues 33,586 11,289 979 (1,849) 44,005 Net realized investment results from certain equity method investments — 103 — — 103 Adjusted revenues $ 33,586 $ 11,392 $ 979 $ (1,849) $ 44,108 Income (loss) before taxes $ 870 $ 859 $ 215 $ (395) $ 1,549 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) (1) (5) — (17) Net realized investment (gains) losses (1) — 406 16 — 422 Amortization of acquired intangible assets 443 15 — — 458 Special items Integration and transaction-related costs — — — 52 52 Pre-tax adjusted income (loss) from operations $ 1,302 $ 1,279 $ 226 $ (343) $ 2,464 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2021 Revenues from external customers $ 29,419 $ 10,285 $ 876 $ — $ 40,580 Inter-segment revenues 1,198 509 — (1,707) Net investment income 3 259 129 — 391 Total revenues 30,620 11,053 1,005 (1,707) 40,971 Net realized investment results from certain equity method investments — 14 — — 14 Adjusted revenues $ 30,620 $ 11,067 $ 1,005 $ (1,707) $ 40,985 Income (loss) before taxes $ 749 $ 1,045 $ 206 $ (487) $ 1,513 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (5) (1) (6) — (12) Net realized investment (gains) losses (1) 2 (16) 27 — 13 Amortization of acquired intangible assets 477 14 4 — 495 Special items Integration and transaction-related costs — — — 29 29 Debt extinguishment costs — — — 131 131 (Benefits) charges associated with litigation matters — — — (27) (27) Pre-tax adjusted income (loss) from operations $ 1,223 $ 1,042 $ 231 $ (354) $ 2,142 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three months ended March 31: Three Months Ended March 31, (In millions) 2022 2021 Products (Pharmacy revenues) (ASC 606) Network revenues $ 15,531 $ 15,138 Home delivery and specialty revenues 14,699 12,774 Other 1,712 1,388 Intercompany eliminations (1,245) (1,275) Total pharmacy revenues 30,697 28,025 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 3,720 3,523 Stop loss 1,325 1,194 Other 360 310 U.S. Government Medicare Advantage 2,078 2,092 Medicare Part D 401 450 Other 940 1,138 International Health 702 641 Total Cigna Healthcare 9,526 9,348 International businesses held for sale 763 809 Other 69 58 Intercompany eliminations (2) (1) Total premiums 10,356 10,214 Services (Fees) (ASC 606) Evernorth 1,624 1,314 Cigna Healthcare 1,496 1,434 Other Operations 5 5 Other revenues 15 19 Intercompany eliminations (602) (431) Total fees and other revenues 2,538 2,341 Total revenues from external customers $ 43,591 $ 40,580

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted	Recent Accounting Pronouncements There were no new accounting standards adopted as of March 31, 2022 that had a material impact on our financial statements. There are no accounting pronouncements not yet adopted, with the exception of Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Insurance Contracts
Unpaid Claims and Claims Expenses	This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. This liability includes amounts from the International Health businesses now reported in Cigna Healthcare following our change in segment reporting in 2021. The prior year roll forward has been updated to reflect this segment change.
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 for additional information on reinsuranceThe Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2021 Form 10-K.
Investments	Cigna's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments.Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2021 Form 10-K. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.
Derivative Financial Instruments	The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company has written and purchased GMIB reinsurance contracts in its run-off reinsurance business that are accounted for as freestanding derivatives as discussed in Note 10. Derivatives in the Company's separate accounts are excluded from the following discussion because associated gains and losses generally accrue directly to separate account policyholders. Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments.
Fair Value Measurements	The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive (loss), net of tax in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Variable Interest Entities	For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2021 Form 10-K.
Separate Accounts	Separate Accounts The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.
AOCI	AOCI includes net unrealized appreciation (depreciation) on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (see Note 11), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.
Guarantees	Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of March 31, 2022 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.Guaranty Fund AssessmentsThe Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.
Commitment and Contingencies	The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accruals for the matters discussed below under "Litigation Matters" and "Regulatory Matters" are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation.
Segment Information	Intersegment revenues primarily reflect pharmacy related transactions between the Evernorth and Cigna Healthcare segments.The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income/loss attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.
Revenues and Costs	Evernorth may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Accounts Receivable, Net	The following amounts were included within Accounts receivable, net: (In millions) March 31, 2022 December 31, 2021 Noninsurance customer receivables $ 7,200 $ 6,274 Pharmaceutical manufacturers receivables 5,805 5,463 Insurance customer receivables 2,647 2,932 Other receivables 399 456 Total 16,051 15,125 Accounts receivable, net classified as Assets of businesses held for sale (48) (54) Accounts receivable, net per Consolidated Balance Sheets $ 16,003 $ 15,071

Assets and Liabilities of Bus_2

Assets and Liabilities of Businesses Held for Sale (Tables)	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Business Held for Sale	The assets and liabilities of businesses held for sale were as follows: (In millions) March 31, 2022 December 31, 2021 Cash and cash equivalents $ 591 $ 406 Investments 4,771 5,109 Deferred policy acquisition costs 2,717 2,755 Separate account assets 718 878 Goodwill, other intangible assets and all other assets 896 909 Total assets of businesses held for sale 9,693 10,057 Insurance and contractholder liabilities 4,562 4,644 Accounts payable, accrued expenses and other liabilities 436 452 Deferred tax liabilities, net 400 449 Separate account liabilities 718 878 Total liabilities of businesses held for sale $ 6,116 $ 6,423

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share were computed as follows: Three Months Ended March 31, 2022 March 31, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 1,183 $ 1,183 $ 1,161 $ 1,161 Shares: Weighted average 318,487 318,487 348,248 348,248 Common stock equivalents 2,795 2,795 3,728 3,728 Total shares 318,487 2,795 321,282 348,248 3,728 351,976 EPS $ 3.71 $ (0.03) $ 3.68 $ 3.33 $ (0.03) $ 3.30
Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share	The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended March 31, (In millions) 2022 2021 Anti-dilutive options 2.8 1.5

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Outstanding Amounts of Debt and Finance Leases	The outstanding amounts of debt and finance leases were as follows: (In millions) March 31, 2022 December 31, 2021 Short-term debt Commercial paper $ 1,570 $ 2,027 $500 million, 3.05% Notes due 11/2022 496 495 $17 million, 8.3% Notes due 1/2023 17 — $63 million, 7.65% Notes due 3/2023 63 — Other, including finance leases 27 23 Total short-term debt $ 2,173 $ 2,545 Long-term debt $17 million, 8.3% Notes due 2023 $ — $ 17 $63 million, 7.65% Notes due 2023 — 63 $700 million, Floating Rate Notes due 2023 699 699 $1,000 million, 3% Notes due 2023 987 985 $1,187 million, 3.75% Notes due 2023 1,185 1,185 $500 million, 0.613% Notes due 2024 499 498 $1,000 million, 3.5% Notes due 2024 985 983 $900 million, 3.25% Notes due 2025 897 897 $2,200 million, 4.125% Notes due 2025 2,193 2,193 $1,500 million, 4.5% Notes due 2026 1,504 1,504 $800 million, 1.25% Notes due 2026 797 796 $1,500 million, 3.4% Notes due 2027 1,426 1,423 $259 million, 7.875% Debentures due 2027 259 259 $600 million, 3.05% Notes due 2027 596 596 $3,800 million, 4.375% Notes due 2028 3,783 3,782 $1,500 million, 2.4% Notes due 2030 1,491 1,490 $1,500 million, 2.375% Notes due 2031 (1) 1,448 1,500 $45 million, 8.3% Step Down Notes due 2033 45 45 $190 million, 6.15% Notes due 2036 190 190 $2,200 million, 4.8% Notes due 2038 2,192 2,192 $750 million, 3.2% Notes due 2040 743 743 $121 million, 5.875% Notes due 2041 119 119 $448 million, 6.125% Notes due 2041 488 490 $317 million, 5.375% Notes due 2042 315 315 $1,500 million, 4.8% Notes due 2046 1,465 1,465 $1,000 million, 3.875% Notes due 2047 989 988 $3,000 million, 4.9% Notes due 2048 2,968 2,967 $1,250 million, 3.4% Notes due 2050 1,236 1,236 $1,500 million, 3.4% Notes due 2051 1,477 1,477 Other, including finance leases 37 28 Total long-term debt $ 31,013 $ 31,125 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 for further information about the Company's interest rate risk management and these derivative instruments.

Common and Preferred Stock (Tab

Common and Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Dividend Payments	The following table provides details of Cigna's dividend payments for the three months ended March 31: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2022 March 9, 2022 March 24, 2022 $1.12 $357 2021 March 10, 2021 March 25, 2021 $1.00 $345

Insurance and Contractholder _2

Insurance and Contractholder Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Insurance Loss Reserves [Abstract]
Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses	The Company's insurance and contractholder liabilities were comprised of the following: March 31, 2022 December 31, 2021 March 31, 2021 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 368 $ 6,641 $ 7,009 $ 352 $ 6,702 $ 7,054 $ 7,161 Future policy benefits 237 8,896 9,133 312 9,194 9,506 9,306 Unearned premiums 619 416 1,035 558 418 976 950 Unpaid claims and claim expenses Cigna Healthcare 4,459 32 4,491 4,159 102 4,261 4,027 Other Operations 503 231 734 548 180 728 723 Total 6,186 16,216 22,402 5,929 16,596 22,525 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (513) (4,049) (4,562) (611) (4,033) (4,644) Total insurance and contractholder liabilities $ 5,673 $ 12,167 $ 17,840 $ 5,318 $ 12,563 $ 17,881 $ 22,167 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.7 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of March 31, 2022 and $3.8 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of December 31, 2021. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment for the three months ended March 31 was as follows: Three Months Ended (In millions) March 31, 2022 March 31, 2021 Beginning balance $ 4,261 $ 3,695 Less: Reinsurance and other amounts recoverable 261 237 Beginning balance, net 4,000 3,458 Incurred costs related to: Current year 8,024 7,755 Prior years (276) (233) Total incurred 7,748 7,522 Paid costs related to: Current year 4,634 4,640 Prior years 2,822 2,555 Total paid 7,456 7,195 Ending balance, net 4,292 3,785 Add: Reinsurance and other amounts recoverable 199 242 Ending balance $ 4,491 $ 4,027 Liability balance details. The liability details for unpaid claims and claim expenses are as follows. The liability balance no longer includes the International Health businesses now reported in Cigna Healthcare following our change in segment reporting. The prior year roll forward has been updated to reflect the segment change. (In millions) March 31, 2022 March 31, 2021 Other Operations International businesses to be sold and our interest in a joint venture in Turkey $ 436 $ 442 Other Operations 298 281 Unpaid claims and claim expenses Other Operations $ 734 $ 723 Activity in the unpaid claims and claim expenses for international businesses held for sale and our interest in a joint venture in Turkey is presented in the following table. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been largely reinsured. Three Months Ended (In millions) March 31, 2022 (1) March 31, 2021 Beginning balance $ 447 $ 452 Less: Reinsurance 46 45 Beginning balance, net 401 407 Incurred claims related to: Current year 259 254 Prior years (7) — Total incurred 252 254 Paid claims related to: Current year 116 115 Prior years 135 134 Total paid 251 249 Foreign currency (6) (15) Ending balance, net 396 397 Add: Reinsurance 40 45 Ending balance $ 436 $ 442
Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses	Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions for the three months ended March 31 were as follows: Three Months Ended (Dollars in millions) March 31, 2022 March 31, 2021 $ % (1) $ % (2) Actual completion factors $ 99 0.3 % $ 107 0.4 % Medical cost trend 177 0.6 126 0.4 Total favorable variance $ 276 0.9 % $ 233 0.8 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2021. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2020.

Reinsurance (Tables)

Reinsurance (Tables)	3 Months Ended
	Mar. 31, 2022
Reinsurance Disclosures [Abstract]
Reinsurance Recoverables by Range of External Credit Rating and Collateral Level	The Company's reinsurance recoverables as of March 31, 2022 are presented in the following table by range of external credit rating and collateral level: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 176 $ 176 BBB- to BBB+ equivalent current credit ratings (1) — — 61 61 Not rated 116 — 43 159 Total recoverables related to ongoing operations (2) 116 — 280 396 Acquisition, disposition or run-off activities A- equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,908 — 2,908 Berkshire Hathaway Life Insurance Company of Nebraska 268 376 — 644 Prudential Retirement Insurance and Annuity 149 — — 149 Prudential Insurance Company of America 404 — — 404 Life Insurance Company of North America — 437 — 437 Other 219 16 16 251 Not rated — 13 3 16 Total recoverables related to acquisition, disposition or run-off activities 1,040 3,750 19 4,809 Total $ 1,156 $ 3,750 $ 299 $ 5,205 Allowance for uncollectible reinsurance (30) Total reinsurance recoverables (2) $ 5,175 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $143 million of current reinsurance recoverables that are reported in Other current assets and $95 million of recoverables classified as Assets of businesses held for sale as of March 31, 2022. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.
Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death	The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) March 31, 2022 December 31, 2021 Account value $ 9,057 $ 9,795 Net amount at risk $ 1,508 $ 1,392 Number of contractholders (estimated) 165,000 170,000
Schedule of Derivative Assets at Fair Value	GMIB liabilities totaling $514 million as of March 31, 2022 and $572 million as of December 31, 2021 are classified as Level 3 because fair value inputs are largely unobservable. The GMIB liabilities reflect the Company's credit risk, while the reinsurance recoverable reflects the credit risk of the reinsurers. There were three reinsurers covering 100% of the GMIB exposures as of March 31, 2022 and December 31, 2021 as follows: (In millions) Line of Business Reinsurer March 31, 2022 December 31, 2021 Collateral and Other Terms at March 31, 2022 GMIB Berkshire $ 257 $ 283 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 151 167 Liberty Re (Bermuda) Ltd. 138 151 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 546 $ 601 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Investments [Abstract]
Investments by category and current or long-term classification	The following table summarizes the Company's investments by category and current or long-term classification: March 31, 2022 December 31, 2021 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 803 $ 14,611 $ 15,414 $ 796 $ 16,162 $ 16,958 Equity securities 50 821 871 — 603 603 Commercial mortgage loans 13 1,546 1,559 40 1,526 1,566 Policy loans — 1,316 1,316 — 1,338 1,338 Other long-term investments — 3,845 3,845 — 3,574 3,574 Short-term investments 190 — 190 428 — 428 Total 1,056 22,139 23,195 1,264 23,203 24,467 Investments classified as assets of businesses held for sale (1) (325) (4,446) (4,771) (344) (4,765) (5,109) Investments per Consolidated Balance Sheets $ 731 $ 17,693 $ 18,424 $ 920 $ 18,438 $ 19,358
Debt Securities by Contractual Maturity	The amortized cost and fair value by contractual maturity periods for debt securities were as follows at March 31, 2022: (In millions) Amortized Fair Due in one year or less $ 796 $ 799 Due after one year through five years 4,978 4,948 Due after five years through ten years 4,967 4,859 Due after ten years 4,163 4,410 Mortgage and other asset-backed securities 413 398 Total $ 15,317 $ 15,414
Gross Unrealized Appreciation (Depreciation) on Debt Securities	Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair March 31, 2022 Federal government and agency $ 298 $ — $ 75 $ (4) $ 369 State and local government 158 — 4 (3) 159 Foreign government 2,467 — 142 (114) 2,495 Corporate 11,981 (23) 409 (374) 11,993 Mortgage and other asset-backed 413 — 4 (19) 398 Total $ 15,317 $ (23) $ 634 $ (514) $ 15,414 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,297 $ (5) $ 412 $ (52) $ 2,652 December 31, 2021 Federal government and agency $ 287 $ — $ 101 $ (1) $ 387 State and local government 154 — 17 — 171 Foreign government 2,468 — 194 (46) 2,616 Corporate 12,361 (23) 1,008 (80) 13,266 Mortgage and other asset-backed 505 — 17 (4) 518 Total $ 15,775 $ (23) $ 1,337 $ (131) $ 16,958 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,262 $ (5) $ 720 $ (10) $ 2,967 (1) Net unrealized appreciation for these investments is excluded from Accumulated other comprehensive loss.
Summary of Debt Securities with a Decline in Fair Value	The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. These debt securities are primarily corporate securities with a decline in fair value that reflects an increase in market yields since purchase. Our allowance for credit losses on debt securities was not material as of March 31, 2022 and December 31, 2021. March 31, 2022 December 31, 2021 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 5,398 $ 5,730 $ (332) 1,761 $ 2,785 $ 2,861 $ (76) 909 Below investment grade 957 1,006 (49) 1,406 561 578 (17) 781 More than one year Investment grade 816 930 (114) 348 382 412 (30) 143 Below investment grade 226 245 (19) 137 162 170 (8) 53 Total $ 7,397 $ 7,911 $ (514) 3,652 $ 3,890 $ 4,021 $ (131) 1,886
Equity Security Investments	The following table provides the values of the Company's equity security investments as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 840 $ 464 $ 257 $ 207 Equity securities with no readily determinable fair value 280 407 270 396 Total $ 1,120 $ 871 $ 527 $ 603
Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio	The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio as of March 31, 2022 and December 31, 2021: (Dollars in millions) March 31, 2022 December 31, 2021 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 555 2.21 $ 560 2.18 60% to 79% 882 1.89 883 1.89 80% to 100% 129 1.47 129 1.47 Allowance for credit losses (7) (6) Total $ 1,559 1.97 61 % $ 1,566 1.96 61 %
Carrying Value Information for Other Long-Term Investments	The following table provides the carrying value information for these investments: Carrying value as of (In millions) March 31, 2022 December 31, 2021 Real estate investments $ 1,212 $ 1,152 Securities partnerships 2,463 2,272 Other 170 150 Total $ 3,845 $ 3,574
Summary of Derivative Instruments Held	As of March 31, 2022 and December 31, 2021, the effects of derivative financial instruments used in these individual hedging strategies were not material to the Consolidated Financial Statements, including gains or losses reclassified from Accumulated other comprehensive loss into Shareholders' net income, amounts excluded from the assessment of hedge effectiveness and fair values of assets posted or held as collateral supporting the fair values of these derivative financial instruments. The following table summarizes the types and notional quantity of derivative instruments held by the Company: Notional Value as of (In millions) March 31, 2022 December 31, 2021 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Foreign currency swap contracts $ 1,110 $ 1,081 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 750 $ 750 Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. Foreign currency swap contracts $ 526 $ 526 Foreign currency forward contracts $ 1,360 $ 1,380 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts $ 749 $ 720
Realized Gains and Losses on Investments	The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended March 31, (In millions) 2022 2021 Net realized investment gains (losses), excluding credit loss expense and asset write-downs $ (319) $ 10 Credit loss (expense) recoveries — (9) Net realized investment gains (losses), before income taxes $ (319) $ 1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Financial Liabilities Carried at Fair Value	The following table provides information as of March 31, 2022 and December 31, 2021 about the Company's financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to policyholders. (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of March 31, 2022 As of December 31, 2021 As of March 31, 2022 As of December 31, 2021 As of March 31, 2022 As of December 31, 2021 As of March 31, 2022 As of December 31, 2021 Financial assets at fair value Debt securities Federal government and agency $ 149 $ 147 $ 220 $ 240 $ — $ — $ 369 $ 387 State and local government — — 159 171 — — 159 171 Foreign government — — 2,490 2,611 5 5 2,495 2,616 Corporate — — 11,468 12,606 525 660 11,993 13,266 Mortgage and other asset-backed — — 273 418 125 100 398 518 Total debt securities 149 147 14,610 16,046 655 765 15,414 16,958 Equity securities (1) 12 16 421 160 31 31 464 207 Short-term investments — — 190 428 — — 190 428 Derivative assets — — 159 143 — — 159 143 Financial liabilities at fair value Derivative liabilities $ — $ — $ 29 $ 33 $ — $ — $ 29 $ 33
Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities	The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of March 31, 2022 and December 31, 2021. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions ) March 31, 2022 December 31, 2021 Unobservable input March 31, 2022 March 31, 2022 December 31, 2021 Debt securities Corporate and government debt securities $ 529 $ 664 Liquidity 60 - 1200 (370) bps 60 - 1060 (410) bps Mortgage and other asset-backed securities 125 100 Liquidity 60 - 380 (130) bps 60 - 390 (100) bps Other debt securities 1 1 Total Level 3 debt securities $ 655 $ 765
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value	The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three months ended March 31, 2022 and 2021. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended (In millions) 2022 2021 Debt and Equity Securities Beginning balance $ 796 $ 854 Total gains (losses) included in shareholders' net income 12 (10) Gains (losses) included in other comprehensive income (15) (16) Gains (losses) required to adjust future policy benefits for settlement annuities (1) (12) (8) Purchases, sales and settlements Purchases 49 29 Settlements (81) (16) Total purchases, sales and settlements (32) 13 Transfers into/(out of) Level 3 Transfers into Level 3 101 86 Transfers out of Level 3 (164) (16) Total transfers into/(out of) Level 3 (63) 70 Ending balance $ 686 $ 903 Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date $ — $ (11) Change in unrealized gains or losses included in Other comprehensive (loss), net of tax for assets held at the end of the reporting period $ (13) $ (16) (1) Amounts do not accrue to shareholders.
Fair Values of Separate Account Assets	Fair values of Separate account assets at March 31, 2022 and December 31, 2021 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 Guaranteed separate accounts (See Note 18) $ 239 $ 227 $ 271 $ 276 $ — $ — $ 510 $ 503 Non-guaranteed separate accounts (1) 460 1,130 6,676 6,406 311 334 7,447 7,870 Subtotal $ 699 $ 1,357 $ 6,947 $ 6,682 $ 311 $ 334 7,957 8,373 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 909 842 Total 8,866 9,215 Separate account assets of businesses classified as held for sale (2) (718) (878) Separate account assets per Consolidated Balance Sheets $ 8,148 $ 8,337 (1) Non-guaranteed separate accounts include $4.4 billion as of March 31, 2022 and $4.5 billion as of December 31, 2021 in assets supporting the Company's pension plans, including $0.3 billion classified in Level 3 as of March 31, 2022 and December 31, 2021. (2) Investments related to the international life, accident and supplemental benefits businesses that are held for sale. See Note 5 to the Consolidated Financial Statements for additional information.
Additional Information on Separate Account Assets Priced at NAV	Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of March 31, 2022 Redemption Frequency Redemption Notice (In millions) March 31, 2022 December 31, 2021 Securities partnerships $ 557 $ 513 $ 262 Not applicable Not applicable Real estate funds 348 325 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 909 $ 842 $ 262
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value	The following table includes the Company's financial instruments not recorded at fair value, however fair value disclosure is required at March 31, 2022 and December 31, 2021. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy March 31, 2022 December 31, 2021 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,519 $ 1,559 $ 1,598 $ 1,566 Long-term debt, including current maturities, excluding finance leases Level 2 $ 32,646 $ 31,552 $ 35,621 $ 31,593

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in the Components of AOCI	Changes in the components of AOCI were as follows: Three Months Ended March 31, (In millions) 2022 2021 Securities and Derivatives Beginning balance $ 685 $ 900 (Depreciation) appreciation on securities and derivatives (705) (342) Tax benefit 154 65 Net (depreciation) appreciation on securities and derivatives (551) (277) Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses) (11) 5 Reclassification adjustment for tax expense (benefit) included in Shareholders' net income 2 (1) Net (gains) losses reclassified from AOCI to Shareholders' net income (9) 4 Other comprehensive (loss), net of tax (560) (273) Ending balance $ 125 $ 627 Translation of foreign currencies Beginning balance $ (233) $ (15) Translation of foreign currencies (60) (114) Tax (expense) (3) (5) Other comprehensive (loss), net of tax (63) (119) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests (2) (4) Shareholders' other comprehensive (loss), net of tax (61) (115) Ending balance $ (294) $ (130) Postretirement benefits liability Beginning balance $ (1,336) $ (1,746) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 16 20 Reclassification adjustment for settlement (Interest expense and other) — 3 Reclassification adjustment for tax (benefit) included in Shareholders' net income (3) (5) Net adjustments reclassified from AOCI to Shareholders' net income 13 18 Other comprehensive income, net of tax 13 18 Ending balance $ (1,323) $ (1,728)

Organizational Efficiency Plan

Organizational Efficiency Plan (Tables)	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Rollforward of Accrued Liability	The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities: (In millions) Balance, December 31, 2021 $ 103 2022 payments (14) Balance, March, 31, 2022 $ 89

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities	Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) March 31, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 456 $ 478 Accrued expenses and other liabilities $ 154 $ 159 Other non-current liabilities 407 436 Total operating lease liabilities $ 561 $ 595 Finance leases: Property and equipment, gross $ 118 $ 101 Accumulated depreciation (56) (51) Property and equipment, net $ 62 $ 50 Short-term debt $ 27 $ 23 Long-term debt 37 28 Total finance lease liabilities $ 64 $ 51 (1) Operating leases include $28 million as of March 31, 2022 and $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $25 million as of March 31, 2022, and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Special Items	The following tables present the special items recorded by the Company for the three months ended March 31, 2022 and 2021: Three Months Ended (In millions) March 31, 2022 March 31, 2021 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax Integration and transaction-related costs $ 37 $ 52 $ 22 $ 29 Debt extinguishment costs — — 101 131 (Benefits) charges associated with litigation matters — — (21) (27) Total impact from special items $ 37 $ 52 $ 102 $ 133
Summarized Segment Financial Information	Summarized segment financial information was as follows: (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2022 Revenues from external customers $ 32,289 $ 10,461 $ 841 $ — $ 43,591 Inter-segment revenues 1,287 562 — (1,849) Net investment income 10 266 138 — 414 Total revenues 33,586 11,289 979 (1,849) 44,005 Net realized investment results from certain equity method investments — 103 — — 103 Adjusted revenues $ 33,586 $ 11,392 $ 979 $ (1,849) $ 44,108 Income (loss) before taxes $ 870 $ 859 $ 215 $ (395) $ 1,549 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) (1) (5) — (17) Net realized investment (gains) losses (1) — 406 16 — 422 Amortization of acquired intangible assets 443 15 — — 458 Special items Integration and transaction-related costs — — — 52 52 Pre-tax adjusted income (loss) from operations $ 1,302 $ 1,279 $ 226 $ (343) $ 2,464 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2021 Revenues from external customers $ 29,419 $ 10,285 $ 876 $ — $ 40,580 Inter-segment revenues 1,198 509 — (1,707) Net investment income 3 259 129 — 391 Total revenues 30,620 11,053 1,005 (1,707) 40,971 Net realized investment results from certain equity method investments — 14 — — 14 Adjusted revenues $ 30,620 $ 11,067 $ 1,005 $ (1,707) $ 40,985 Income (loss) before taxes $ 749 $ 1,045 $ 206 $ (487) $ 1,513 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (5) (1) (6) — (12) Net realized investment (gains) losses (1) 2 (16) 27 — 13 Amortization of acquired intangible assets 477 14 4 — 495 Special items Integration and transaction-related costs — — — 29 29 Debt extinguishment costs — — — 131 131 (Benefits) charges associated with litigation matters — — — (27) (27) Pre-tax adjusted income (loss) from operations $ 1,223 $ 1,042 $ 231 $ (354) $ 2,142
Revenue from External Customers	Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three months ended March 31: Three Months Ended March 31, (In millions) 2022 2021 Products (Pharmacy revenues) (ASC 606) Network revenues $ 15,531 $ 15,138 Home delivery and specialty revenues 14,699 12,774 Other 1,712 1,388 Intercompany eliminations (1,245) (1,275) Total pharmacy revenues 30,697 28,025 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 3,720 3,523 Stop loss 1,325 1,194 Other 360 310 U.S. Government Medicare Advantage 2,078 2,092 Medicare Part D 401 450 Other 940 1,138 International Health 702 641 Total Cigna Healthcare 9,526 9,348 International businesses held for sale 763 809 Other 69 58 Intercompany eliminations (2) (1) Total premiums 10,356 10,214 Services (Fees) (ASC 606) Evernorth 1,624 1,314 Cigna Healthcare 1,496 1,434 Other Operations 5 5 Other revenues 15 19 Intercompany eliminations (602) (431) Total fees and other revenues 2,538 2,341 Total revenues from external customers $ 43,591 $ 40,580

Description of Business (Detail

Description of Business (Details) $ in Millions	Oct. 31, 2021USD ($)
International life, accident and supplemental benefits businesses | Held-for-Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	$ 5,720

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Noninsurance customer receivables	$ 7,200	$ 6,274
Pharmaceutical manufacturers receivables	5,805	5,463
Insurance customer receivables	2,647	2,932
Other receivables	399	456
Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale	16,051	15,125
Accounts receivable, net classified as Assets of businesses held for sale	(48)	(54)
Accounts receivable, net per Consolidated Balance Sheets	$ 16,003	$ 15,071

Accounts Receivable, Net - Narr

Accounts Receivable, Net - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Allowance for receivables net current	$ 1,500	$ 1,400
Allowance for current expected credit losses on accounts receivable	$ 65	$ 60

Mergers, Acquisitions and Div_2

Mergers, Acquisitions and Divestitures - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Apr. 19, 2021
Business Acquisition [Line Items]
Goodwill	$ 45,804		$ 45,811
Acquired intangible assets	33,714		$ 34,102
Integration and transaction-related costs (Selling, general and administrative expenses)	52	$ 29
Integration and transaction-related costs, after-tax	$ 37	$ 22
MDLIVE, Inc.
Business Acquisition [Line Items]
Ownership interest acquired				97.00%
Ownership interest after acquisition				100.00%

Assets and Liabilities of Bus_3

Assets and Liabilities of Businesses Held for Sale (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021	Oct. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Separate account assets	$ 718	$ 878
Assets of businesses held for sale	9,693	10,057
Insurance and contractholder liabilities	4,562	4,644
Total liabilities of businesses held for sale	6,116	6,423
International life, accident and supplemental benefits businesses | Held-for-Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price			$ 5,720
Cash and cash equivalents	591	406
Investments	4,771	5,109
Deferred policy acquisition costs	2,717	2,755
Separate account assets	718	878
Goodwill, other intangible assets and all other assets	896	909
Assets of businesses held for sale	9,693	10,057
Insurance and contractholder liabilities	4,562	4,644
Accounts payable, accrued expenses and other liabilities	436	452
Deferred tax liabilities, net	400	449
Separate account liabilities	718	878
Total liabilities of businesses held for sale	6,116	6,423
Gross unrealized appreciation on securities and derivatives	(33)	137
Gross translation loss on foreign currencies	$ 160	$ 209

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Shareholders' net income	$ 1,183	$ 1,161
Shares:
Weighted average (in shares)	318,487	348,248
Common stock equivalents (in shares)	2,795	3,728
Total shares (in shares)	321,282	351,976
EPS, basic (in dollars per share)	$ 3.71	$ 3.33
EPS, effect of dilution (in dollars per share)	(0.03)	(0.03)
EPS, diluted (in dollars per share)	$ 3.68	$ 3.30

Earnings Per Share - Outstandin

Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options (in shares)	2.8	1.5

Earnings Per Share - Shares of

Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares shares in Millions	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Earnings Per Share [Abstract]
Shares of common stock held in treasury	77.3	71.2	48.7

Debt - Outstanding Amounts of D

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-term debt
Commercial paper	$ 1,570,000,000	$ 2,027,000,000
Other, including finance leases	27,000,000	23,000,000
Total short-term debt	2,173,000,000	2,545,000,000
Long-term debt
Other, including finance leases	37,000,000	28,000,000
Total long-term debt	31,013,000,000	31,125,000,000
$500 million, 3.05% Notes due 11/2022
Short-term debt
Current maturities	496,000,000	495,000,000
Long-term debt
Gross value		$ 500,000,000
Interest Rate		3.05%
$17 million, 8.3% Notes due 2023
Short-term debt
Current maturities	17,000,000	$ 0
Long-term debt
Long-term debt	0	17,000,000
Gross value	$ 17,000,000
Interest Rate	8.30%
$63 million, 7.65% Notes due 2023
Short-term debt
Current maturities	$ 63,000,000	0
Long-term debt
Long-term debt	0	63,000,000
Gross value	$ 63,000,000
Interest Rate	7.65%
$700 million, Floating Rate Notes due 2023
Long-term debt
Long-term debt	$ 699,000,000	699,000,000
Gross value	700,000,000
$1,000 million, 3% Notes due 2023
Long-term debt
Long-term debt	987,000,000	985,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.00%
$1,187 million, 3.75% Notes due 2023
Long-term debt
Long-term debt	$ 1,185,000,000	1,185,000,000
Gross value	$ 1,187,000,000
Interest Rate	3.75%
$500 million, 0.613% Notes due 2024
Long-term debt
Long-term debt	$ 499,000,000	498,000,000
Gross value	$ 500,000,000
Interest Rate	0.613%
$1,000 million, 3.5% Notes due 2024
Long-term debt
Long-term debt	$ 985,000,000	983,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.50%
$900 million, 3.25% Notes due 2025
Long-term debt
Long-term debt	$ 897,000,000	897,000,000
Gross value	$ 900,000,000
Interest Rate	3.25%
$2,200 million, 4.125% Notes due 2025
Long-term debt
Long-term debt	$ 2,193,000,000	2,193,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.125%
$1,500 million, 4.5% Notes due 2026
Long-term debt
Long-term debt	$ 1,504,000,000	1,504,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.50%
$800 million, 1.25% Notes due 2026
Long-term debt
Long-term debt	$ 797,000,000	796,000,000
Gross value	$ 800,000,000
Interest Rate	1.25%
$1,500 million, 3.4% Notes due 2027
Long-term debt
Long-term debt	$ 1,426,000,000	1,423,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%
$259 million, 7.875% Debentures due 2027
Long-term debt
Long-term debt	$ 259,000,000	259,000,000
Gross value	$ 259,000,000
Interest Rate	7.875%
$600 million, 3.05% Notes due 2027
Long-term debt
Long-term debt	$ 596,000,000	596,000,000
Gross value	$ 600,000,000
Interest Rate	3.05%
$3,800 million, 4.375% Notes due 2028
Long-term debt
Long-term debt	$ 3,783,000,000	3,782,000,000
Gross value	$ 3,800,000,000
Interest Rate	4.375%
$1,500 million, 2.4% Notes due 2030
Long-term debt
Long-term debt	$ 1,491,000,000	1,490,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.40%
$1,500 million, 2.375% Notes due 2031
Long-term debt
Long-term debt	$ 1,448,000,000	1,500,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.375%
$45 million, 8.3% Step Down Notes due 2033
Long-term debt
Long-term debt	$ 45,000,000	45,000,000
Gross value	$ 45,000,000
Interest Rate	8.30%
$190 million, 6.15% Notes due 2036
Long-term debt
Long-term debt	$ 190,000,000	190,000,000
Gross value	$ 190,000,000
Interest Rate	6.15%
$2,200 million, 4.8% Notes due 2038
Long-term debt
Long-term debt	$ 2,192,000,000	2,192,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.80%
$750 million, 3.2% Notes due 2040
Long-term debt
Long-term debt	$ 743,000,000	743,000,000
Gross value	$ 750,000,000
Interest Rate	3.20%
$121 million, 5.875% Notes due 2041
Long-term debt
Long-term debt	$ 119,000,000	119,000,000
Gross value	$ 121,000,000
Interest Rate	5.875%
$448 million, 6.125% Notes due 2041
Long-term debt
Long-term debt	$ 488,000,000	490,000,000
Gross value	$ 448,000,000
Interest Rate	6.125%
$317 million, 5.375% Notes due 2042
Long-term debt
Long-term debt	$ 315,000,000	315,000,000
Gross value	$ 317,000,000
Interest Rate	5.375%
$1,500 million, 4.8% Notes due 2046
Long-term debt
Long-term debt	$ 1,465,000,000	1,465,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.80%
$1,000 million, 3.875% Notes due 2047
Long-term debt
Long-term debt	$ 989,000,000	988,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.875%
$3,000 million, 4.9% Notes due 2048
Long-term debt
Long-term debt	$ 2,968,000,000	2,967,000,000
Gross value	$ 3,000,000,000
Interest Rate	4.90%
$1,250 million, 3.4% Notes due 2050
Long-term debt
Long-term debt	$ 1,236,000,000	1,236,000,000
Gross value	$ 1,250,000,000
Interest Rate	3.40%
$1,500 million, 3.4% Notes due 2051
Long-term debt
Long-term debt	$ 1,477,000,000	$ 1,477,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%

Debt - Narrative (Details)

Debt - Narrative (Details)	1 Months Ended	3 Months Ended
	Apr. 30, 2022USD ($)bank	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Debt Instrument [Line Items]
Commercial paper average interest rate		0.60%
Interest expense on long-term and short-term debt		$ 314,000,000	$ 325,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity		5,000,000,000
Revolving Credit and Letter of Credit Facility Maturing April 2026, Revolving Credit and Letter of Credit Facility Maturing April 2024, and 364 Day Revolving Credit Agreement Maturing April 2022
Debt Instrument [Line Items]
Outstanding balances		0
Five-year Revolving Credit Agreement, Maturing April 2026
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 3,000,000,000
Credit agreement term		5 years
Three-year Revolving Credit Agreement, Maturing April 2024
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		3 years
364-day Revolving Credit Agreement, Maturing April 2022
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		364 days
Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023 | Subsequent Event
Debt Instrument [Line Items]
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 6,500,000,000
Number of participating banks | bank	22
Leverage ratio covenant	60.00%
Revolving Credit And Letter Of Credit Facility Maturing April 2027 | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 3,000,000,000
Credit agreement term	5 years
Credit agreement extension term	1 year
Revolving Credit And Letter Of Credit Facility Maturing April 2027 | Letter of Credit | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Revolving Credit Facility Maturing April 2025 | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	3 years
Credit agreement extension term	1 year
364 Day Revolving Credit Agreement, Maturing April 2023 | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year

Common and Preferred Stock - Na

Common and Preferred Stock - Narrative (Details) - $ / shares	Apr. 27, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)		$ 1.12	$ 1	$ 1	$ 1	$ 1
Subsequent Event
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)	$ 1.12

Common and Preferred Stock - Di

Common and Preferred Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 24, 2022	Mar. 25, 2021	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Amount per share (in dollars per share)	$ 1.12	$ 1	$ 1.12
Total amount paid	$ 357	$ 345	$ 357	$ 345

Insurance and Contractholder _3

Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Current
Contractholder deposit funds	$ 368	$ 352
Future policy benefits	237	312
Unearned premiums	619	558
Total	6,186	5,929
Insurance and contractholder liabilities classified as held for sale	(513)	(611)
Current insurance and contractholder liabilities	5,673	5,318
Non-current
Contractholder deposit funds	6,641	6,702
Future policy benefits	8,896	9,194
Unearned premiums	416	418
Total	16,216	16,596
Insurance and contractholder liabilities classified as held for sale	(4,049)	(4,033)
Non-current insurance and contractholder liabilities	12,167	12,563
Total
Contractholder deposit funds	7,009	7,054	$ 7,161
Future policy benefits	9,133	9,506
Unearned premiums	1,035	976
Future policy benefits			9,306
Unearned premiums			950
Total	22,402	22,525
Insurance and contractholder liabilities classified as held for sale	(4,562)	(4,644)
Total insurance and contractholder liabilities	17,840	17,881	22,167
Future policy benefits classified as liabilities of business held for sale	3,700	3,800
Unpaid claims classified as liabilities of business held for sale	400	400
Contractholder deposit funds classified as liabilities of business held for sale	400	400
Cigna Healthcare
Current
Unpaid claims and claim expenses	4,459	4,159
Non-current
Unpaid claims and claim expenses	32	102
Total
Unpaid claims and claim expenses	4,491	4,261
Unpaid claims and claim expenses	4,491	4,261	4,027	$ 3,695
Other Operations
Current
Unpaid claims and claim expenses	503	548
Non-current
Unpaid claims and claim expenses	231	180
Total
Unpaid claims and claim expenses	$ 734	$ 728
Unpaid claims and claim expenses			$ 723

Insurance and Contractholder _4

Insurance and Contractholder Liabilities - Narrative (Details) - USD ($) $ in Billions	Mar. 31, 2022	Mar. 31, 2021
Cigna Healthcare
Insurance and Contractholder Liabilities [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process	$ 4.2	$ 3.7

Insurance and Contractholder _5

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - Cigna Healthcare - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance	$ 4,261	$ 3,695
Less: Reinsurance and other amounts recoverable	261	237
Beginning balance, net	4,000	3,458
Incurred costs related to:
Current year	8,024	7,755
Prior years	(276)	(233)
Total incurred	7,748	7,522
Paid costs related to:
Current year	4,634	4,640
Prior years	2,822	2,555
Total paid	7,456	7,195
Ending balance, net	4,292	3,785
Add: Reinsurance and other amounts recoverable	199	242
Ending balance	$ 4,491	$ 4,027

Insurance and Contractholder _6

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 276	$ 233
Favorable (unfavorable) variance, percentage	0.90%	0.80%
Actual completion factors
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 99	$ 107
Favorable (unfavorable) variance, percentage	0.30%	0.40%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 177	$ 126
Favorable (unfavorable) variance, percentage	0.60%	0.40%

Insurance and Contractholder _7

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Other Operations - Liability Balance Details (Details) - Other Operations - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 734	$ 728
Unpaid claims and claim expenses			$ 723
International businesses to be sold and our interest in a joint venture in Turkey
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	436	$ 447
Unpaid claims and claim expenses			442	$ 452
Other Operations
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 298
Unpaid claims and claim expenses			$ 281

Insurance and Contractholder _8

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Other Operations - Activity (Details) - Other Operations - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance, including disposal groups	$ 728
Paid costs related to:
Ending balance		$ 723
Ending balance, including disposal groups	734
International businesses to be sold and our interest in a joint venture in Turkey
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance		452
Less: Reinsurance and other amounts recoverable		45
Beginning balance, net		407
Beginning balance, including disposal groups	447
Less: Reinsurance, including disposal groups	46
Beginning balance, net, including disposal groups	401
Incurred claims related to:
Current year	259	254
Prior years	(7)	0
Total incurred	252	254
Paid costs related to:
Current year	116	115
Prior years	135	134
Total paid	251	249
Foreign currency	(6)	(15)
Ending balance, net		397
Add: Reinsurance and other amounts recoverable		45
Ending balance		$ 442
Ending balance, net, including disposal groups	396
Add: Reinsurance, including disposal groups	40
Ending balance, including disposal groups	$ 436

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)reinsurer	Dec. 31, 2021USD ($)reinsurer
Effects of Reinsurance [Line Items]
Reinsurance recoverables, held for sale	$ 95
GMIB
Effects of Reinsurance [Line Items]
Annuitization election period	30 days
Percent of future claim payments reinsured	100.00%	100.00%
Number of external reinsurers | reinsurer	3	3
GMIB | Other Contract [Member]
Effects of Reinsurance [Line Items]
GMIB liabilities	$ 514	$ 572
Variable Annuity | Berkshire Hathaway Life Insurance Company of Nebraska
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100.00%
Remaining overall limit under reinsurance agreement	$ 3,200
Other Current Assets
Effects of Reinsurance [Line Items]
Reinsurance recoverables	$ 143

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables by Range of External Credit Rating and Collateral Level (Details) $ in Millions	Mar. 31, 2022USD ($)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 5,205
Allowance for uncollectible reinsurance	(30)
Total reinsurance recoverables	5,175
Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,156
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,750
No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	299
Ongoing Operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables	396
Ongoing Operations | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	176
Ongoing Operations | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	61
Ongoing Operations | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	159
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	116
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	116
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	280
Ongoing Operations | No collateral | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	176
Ongoing Operations | No collateral | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	61
Ongoing Operations | No collateral | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	43
Acquisition, disposition or run-off activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables	4,809
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,908
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	644
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	149
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	404
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	437
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	251
Acquisition, disposition or run-off activities | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,040
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	268
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	149
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	404
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	219
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,750
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,908
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	376
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	437
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	13
Acquisition, disposition or run-off activities | No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	19
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or run-off activities | No collateral | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 3

Reinsurance - Account Value, Ne

Reinsurance - Account Value, Net Amount at Risk and Contractholders for GMDB Business (Details) - Variable Annuity - GMDB contractholder in Thousands, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)contractholder	Dec. 31, 2019contractholder	Dec. 31, 2021USD ($)
Net Amount at Risk by Product and Guarantee [Line Items]
Account value	$ 9,057		$ 9,795
Net amount at risk	$ 1,508		$ 1,392
Number of contractholders (estimated) | contractholder	165	170

Reinsurance - GMIB Reinsurers (

Reinsurance - GMIB Reinsurers (Details) - GMIB - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Berkshire | Secured | GMIB Assets | Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100.00%
Liberty Re (Bermuda) Ltd. | Secured | GMIB Assets | Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100.00%
Other Contract [Member]
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 546	$ 601
Other Contract [Member] | Berkshire
Ceded Credit Risk [Line Items]
GMIB recoverables	257	283
Other Contract [Member] | Sun Life Assurance Company of Canada
Ceded Credit Risk [Line Items]
GMIB recoverables	151	167
Other Contract [Member] | Liberty Re (Bermuda) Ltd.
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 138	$ 151

Investments - Investments by Ca

Investments - Investments by Category (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current
Investments including assets of business held for sale	$ 1,056	$ 1,264
Investments classified as assets of business held for sale	(325)	(344)
Investments per Consolidated Balance Sheets	731	920
Long-term
Investments including assets of business held for sale	22,139	23,203
Investments classified as assets of business held for sale	(4,446)	(4,765)
Investments per Consolidated Balance Sheets	17,693	18,438
Total
Investments including assets of business held for sale	23,195	24,467
Investments classified as assets of business held for sale	(4,771)	(5,109)
Investments per Consolidated Balance Sheets	18,424	19,358
Debt securities
Current
Investments including assets of business held for sale	803	796
Long-term
Investments including assets of business held for sale	14,611	16,162
Total
Investments including assets of business held for sale	15,414	16,958
Equity securities
Current
Investments including assets of business held for sale	50	0
Long-term
Investments including assets of business held for sale	821	603
Total
Investments including assets of business held for sale	871	603
Commercial mortgage loans
Current
Investments including assets of business held for sale	13	40
Long-term
Investments including assets of business held for sale	1,546	1,526
Total
Investments including assets of business held for sale	1,559	1,566
Policy loans
Current
Investments including assets of business held for sale	0	0
Long-term
Investments including assets of business held for sale	1,316	1,338
Total
Investments including assets of business held for sale	1,316	1,338
Other long-term investments
Current
Investments including assets of business held for sale	0	0
Long-term
Investments including assets of business held for sale	3,845	3,574
Total
Investments including assets of business held for sale	3,845	3,574
Short-term investments
Current
Investments including assets of business held for sale	190	428
Long-term
Investments including assets of business held for sale	0	0
Total
Investments including assets of business held for sale	$ 190	$ 428

Investments - Debt Securities b

Investments - Debt Securities by Contractual Maturity Periods (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Amortized Cost
Due in one year or less	$ 796
Due after one year through five years	4,978
Due after five years through ten years	4,967
Due after ten years	4,163
Mortgage and other asset-backed securities	413
Total	15,317	$ 15,775
Fair Value
Due in one year or less	799
Due after one year through five years	4,948
Due after five years through ten years	4,859
Due after ten years	4,410
Mortgage and other asset-backed securities	398
Total	$ 15,414

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Schedule of Investments [Line Items]
Gain (loss) recognized in the income statement
Gain (loss) recognized in other comprehensive income
Gains (losses) reclassified from other comprehensive income into shareholders' net income
Amounts excluded from assessment of hedge effectiveness
Fair value of assets posted as collateral supporting the fair values of these derivative financial instruments
Fair value of assets held as collateral supporting the fair values of these derivative financial instruments
Equity Securities FV NI | Product Concentration Risk | Health Care Sector
Schedule of Investments [Line Items]
Concentration percentage	65.00%

Investments - Gross Unrealized

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 15,317	$ 15,775
Allowance for Credit Loss	(23)	(23)
Unrealized Appreciation	634	1,337
Unrealized Depreciation	(514)	(131)
Fair Value	15,414	16,958
Run-Off Settlement Annuity Business
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,297	2,262
Allowance for Credit Loss	(5)	(5)
Unrealized Appreciation	412	720
Unrealized Depreciation	(52)	(10)
Fair Value	2,652	2,967
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	298	287
Allowance for Credit Loss	0	0
Unrealized Appreciation	75	101
Unrealized Depreciation	(4)	(1)
Fair Value	369	387
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	158	154
Allowance for Credit Loss	0	0
Unrealized Appreciation	4	17
Unrealized Depreciation	(3)	0
Fair Value	159	171
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,467	2,468
Allowance for Credit Loss	0	0
Unrealized Appreciation	142	194
Unrealized Depreciation	(114)	(46)
Fair Value	2,495	2,616
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	11,981	12,361
Allowance for Credit Loss	(23)	(23)
Unrealized Appreciation	409	1,008
Unrealized Depreciation	(374)	(80)
Fair Value	11,993	13,266
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	413	505
Allowance for Credit Loss	0	0
Unrealized Appreciation	4	17
Unrealized Depreciation	(19)	(4)
Fair Value	$ 398	$ 518

Investments - Summary of Debt S

Investments - Summary of Debt Securities with a Decline in Fair Value (Details) $ in Millions	Mar. 31, 2022USD ($)position	Dec. 31, 2021USD ($)position
More than one year
Total Fair Value	$ 7,397	$ 3,890
Total Amortized Cost	7,911	4,021
Total Unrealized Depreciation	$ (514)	$ (131)
Total Number of Issues | position	3,652	1,886
Investment grade | Debt securities
One year or less
Fair Value	$ 5,398	$ 2,785
Amortized Cost	5,730	2,861
Unrealized Depreciation	$ (332)	$ (76)
Number of Issues | position	1,761	909
More than one year
Fair Value	$ 816	$ 382
Amortized Cost	930	412
Unrealized Depreciation	$ (114)	$ (30)
Number of Issues | position	348	143
Below investment grade | Debt securities
One year or less
Fair Value	$ 957	$ 561
Amortized Cost	1,006	578
Unrealized Depreciation	$ (49)	$ (17)
Number of Issues | position	1,406	781
More than one year
Fair Value	$ 226	$ 162
Amortized Cost	245	170
Unrealized Depreciation	$ (19)	$ (8)
Number of Issues | position	137	53

Investments - Equity Security I

Investments - Equity Security Investments (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Cost
Equity securities with readily determinable fair values	$ 840	$ 257
Equity securities with no readily determinable fair value	280	270
Total	1,120	527
Carrying Value
Equity securities with readily determinable fair values	464	207
Equity securities with no readily determinable fair value	407	396
Total	$ 871	$ 603

Investments - Summary of the Cr

Investments - Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Schedule of Investments [Line Items]
Allowance for credit losses	$ (7)	$ (6)
Total	$ 1,559	$ 1,566
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.97	1.96
Average Loan-to-Value Ratio	61.00%	61.00%
Below 60%
Schedule of Investments [Line Items]
Carrying Value	$ 555	$ 560
Below 60% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.21	2.18
60% to 79%
Schedule of Investments [Line Items]
Carrying Value	$ 882	$ 883
60% to 79% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.89	1.89
80% to 100%
Schedule of Investments [Line Items]
Carrying Value	$ 129	$ 129
80% to 100% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.47	1.47

Investments - Carrying Values o

Investments - Carrying Values of Other Long-Term Investments (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Schedule of Investments [Line Items]
Other long term investments	$ 3,845	$ 3,574
Real estate investments
Schedule of Investments [Line Items]
Other long term investments	1,212	1,152
Securities partnerships
Schedule of Investments [Line Items]
Other long term investments	2,463	2,272
Other
Schedule of Investments [Line Items]
Other long term investments	$ 170	$ 150

Investments - Summary of Deriva

Investments - Summary of Derivative Instruments Held (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Designated as Hedging Instrument | Fair Value Hedging | Foreign currency swap contracts
Derivative [Line Items]
Notional Value	$ 1,110	$ 1,081
Designated as Hedging Instrument | Fair Value Hedging | Interest rate swap contracts
Derivative [Line Items]
Notional Value	750	750
Designated as Hedging Instrument | Net Investment Hedging | Foreign currency swap contracts
Derivative [Line Items]
Notional Value	526	526
Designated as Hedging Instrument | Net Investment Hedging | Foreign currency forward contracts
Derivative [Line Items]
Notional Value	1,360	1,380
Not Designated as Hedging Instrument, Economic Hedge | Foreign currency forward contracts
Derivative [Line Items]
Notional Value	$ 749	$ 720

Investments - Realized Gains an

Investments - Realized Gains and Losses on Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Investments [Abstract]
Net realized investment gains (losses), excluding credit loss expense and asset write-downs	$ (319)	$ 10
Credit loss (expense) recoveries	0	(9)
Net realized investment gains (losses), before income taxes	$ (319)	$ 1

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Financial assets at fair value:
Debt Securities	$ 15,414	$ 16,958
Equity securities	464	207
Recurring
Financial assets at fair value:
Debt Securities	15,414	16,958
Equity securities	464	207
Short-term investments	190	428
Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	159	143
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	29	33
Recurring | Swaps | Short-term investments
Financial assets at fair value:
Derivative assets
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	149	147
Equity securities	12	16
Short-term investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	14,610	16,046
Equity securities	421	160
Short-term investments	190	428
Significant Other Observable Inputs (Level 2) | Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	159	143
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	29	33
Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	655	765
Equity securities	31	31
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) | Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Federal government and agency
Financial assets at fair value:
Debt Securities	369	387
Federal government and agency | Recurring
Financial assets at fair value:
Debt Securities	369	387
Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	149	147
Federal government and agency | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	220	240
Federal government and agency | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government
Financial assets at fair value:
Debt Securities	159	171
State and local government | Recurring
Financial assets at fair value:
Debt Securities	159	171
State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	159	171
State and local government | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government
Financial assets at fair value:
Debt Securities	2,495	2,616
Foreign government | Recurring
Financial assets at fair value:
Debt Securities	2,495	2,616
Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	2,490	2,611
Foreign government | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	5	5
Corporate
Financial assets at fair value:
Debt Securities	11,993	13,266
Corporate | Recurring
Financial assets at fair value:
Debt Securities	11,993	13,266
Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Corporate | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	11,468	12,606
Corporate | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	525	660
Mortgage and other asset-backed
Financial assets at fair value:
Debt Securities	398	518
Mortgage and other asset-backed | Recurring
Financial assets at fair value:
Debt Securities	398	518
Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	273	418
Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	$ 125	$ 100

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - Separate Account Assets - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), , including transfers in and out of Level 3
Separate accounts assets classified in Level 3, including disposal groups, period increase (decrease), including transfers in and out of Level 3
Recurring | Securities partnerships
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Expected liquidation period after inception	10 years

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 655	$ 765
Corporate and government debt securities | Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 529	$ 664
Corporate and government debt securities | Securities Priced by the Company | Minimum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Corporate and government debt securities | Securities Priced by the Company | Maximum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.1200	0.1060
Corporate and government debt securities | Securities Priced by the Company | Weighted Average | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0370	0.0410
Mortgage and other asset-backed securities | Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 125	$ 100
Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0380	0.0390
Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0130	0.0100
Other debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 1	$ 1

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Transfers into/(out of) Level 3
Change in unrealized gains or losses included in Other comprehensive (loss), net of tax for assets held at the end of the reporting period	$ (13)	$ (16)
Debt and Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance		854
Balance	796
Total gains (losses) included in shareholders' net income	12	(10)
Gains (losses) included in other comprehensive income	(15)	(16)
Gains (losses) required to adjust future policy benefits for settlement annuities	(12)	(8)
Purchases, sales and settlements
Purchases	49	29
Settlements	(81)	(16)
Total purchases, sales and settlements	(32)	13
Transfers into/(out of) Level 3
Transfers into Level 3	101	86
Transfers out of Level 3	(164)	(16)
Total transfers into/(out of) Level 3	(63)	70
Balance		903
Balance	686
Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date	$ 0	$ (11)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Values of Separate Account Assets (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	$ 510	$ 503
Non-guaranteed separate accounts	7,447	7,870
Subtotal	7,957	8,373
Non-guaranteed separate accounts priced at NAV as a practical expedient	909	842
Total	8,866	9,215
Separate account assets of business classified as held for sale	(718)	(878)
Separate account assets	8,148	8,337
Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	4,400	4,500
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	239	227
Non-guaranteed separate accounts	460	1,130
Subtotal	699	1,357
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	271	276
Non-guaranteed separate accounts	6,676	6,406
Subtotal	6,947	6,682
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	0	0
Non-guaranteed separate accounts	311	334
Subtotal	311	334
Significant Unobservable Inputs (Level 3) | Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	$ 300	$ 300

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details) - Separate Account Assets - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 262
Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	909	$ 842
Securities partnerships
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	262
Securities partnerships | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	557	513
Real estate funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Real estate funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Real estate funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Real estate funds | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 348	325
Hedge funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Hedge funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Hedge funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Hedge funds | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 4	$ 4

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Realized investment losses on assets measured at fair value under certain conditions, after-tax	$ 0	$ 0
Realized investment gains on equity securities with no readily determinable fair value

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Fair Value | Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 32,646	$ 35,621
Fair Value | Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,519	1,598
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,559	1,566
Long-term debt, including current maturities, excluding finance leases	$ 31,552	$ 31,593

Variable Interest Entities (Det

Variable Interest Entities (Details) - entity	Mar. 31, 2022	Dec. 31, 2021
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	0	0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 47,130	$ 50,328
Other comprehensive (loss), net of tax	(610)	(374)
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	(2)	(4)
Shareholders other comprehensive income (loss), net of tax	(608)	(370)
Balance	46,109	48,155
Securities and Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	685	900
Other comprehensive income (loss) before reclassifications, before tax	(705)	(342)
Other comprehensive income (loss) before reclassifications, tax	154	65
Other comprehensive income (loss) before reclassifications, after-tax	(551)	(277)
Reclassification adjustment, tax	2	(1)
Net amounts reclassified from AOCI to net income	(9)	4
Shareholders other comprehensive income (loss), net of tax	(560)	(273)
Balance	125	627
Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	(11)	5
Translation of foreign currencies
Accumulated Other Comprehensive Income (Loss) [Line Items]
Translation of foreign currencies, before tax	(60)	(114)
Translation of foreign currencies, tax	(3)	(5)
Other comprehensive (loss), net of tax	(63)	(119)
Translation of foreign currencies attributable to noncontrolling interest
Accumulated Other Comprehensive Income (Loss) [Line Items]
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	(2)	(4)
Translation of foreign currencies attributable to parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(233)	(15)
Shareholders other comprehensive income (loss), net of tax	(61)	(115)
Balance	(294)	(130)
Postretirement benefits liability
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1,336)	(1,746)
Reclassification adjustment, tax	(3)	(5)
Net amounts reclassified from AOCI to net income	13	18
Shareholders other comprehensive income (loss), net of tax	13	18
Balance	(1,323)	(1,728)
Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	16	20
Reclassification adjustment for settlement (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	$ 0	$ 3

Organizational Efficiency Pla_2

Organizational Efficiency Plan - Narrative (Details) $ in Millions	3 Months Ended
	Dec. 31, 2021USD ($)
Restructuring and Related Activities [Abstract]
Charge for organizational efficiency plan (Selling, general and administrative expenses)	$ 168
Charge for organizational efficiency plan (Selling, general and administrative expenses)	119
Restructuring charges, abandonment of leased assets and impairment of property and equipment	59
Restructuring charges, severance costs	$ 109

Organizational Efficiency Pla_3

Organizational Efficiency Plan - Rollforward of Accrued Liability (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Restructuring and Related Activities [Abstract]
Balance, December 31, 2021	$ 103
2022 payments	(14)
Balance, March, 31, 2022	$ 89

Leases - Operating and Finance

Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Operating leases:
Operating lease ROU assets	$ 456	$ 478
Accrued expenses and other liabilities	154	159
Other non-current liabilities	407	436
Total operating lease liabilities	561	595
Finance leases:
Property and equipment, gross	118	101
Accumulated depreciation	(56)	(51)
Property and equipment, net	62	50
Short-term debt	27	23
Long-term debt	37	28
Total finance lease liabilities	$ 64	$ 51
Balance sheet location of operating lease ROU assets	Other assets	Other assets
Balance sheet location of current operating lease liabilities	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Balance sheet location of non-current operating lease liabilities	Other non-current liabilities	Other non-current liabilities
Balance sheet location of non-current finance lease assets	Property and equipment	Property and equipment
Balance sheet location of current finance lease liabilities	Short-term debt	Short-term debt
Balance sheet location of non-current finance lease liabilities	Long-term debt	Long-term debt
Operating lease ROU assets, held for sale	$ 28	$ 27
Operating lease liabilities, held for sale	$ 25	$ 28

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Consolidated effective tax rate	22.70%	22.60%

Contingencies and Other Matte_2

Contingencies and Other Matters (Details)	Mar. 31, 2022USD ($)	Apr. 19, 2016claim	Mar. 31, 2016USD ($)claim	Mar. 31, 2022USD ($)
Guaranty Fund Assessments
Commitments And Contingencies [Line Items]
Loss contingency accrual provision
Litigation Matters and Regulatory Matters
Commitments And Contingencies [Line Items]
Reserves for litigation matters, pre-tax
Express Scripts Litigation with Anthem
Commitments And Contingencies [Line Items]
Number of counts dismissed | claim		2
Number of counts | claim			6
Express Scripts Litigation with Anthem | Judicial Ruling | Pricing Concessions
Commitments And Contingencies [Line Items]
Damages sought by Anthem	14,800,000,000
Express Scripts Litigation with Anthem | Judicial Ruling | Pricing Concessions Through Remaining Contract Term
Commitments And Contingencies [Line Items]
Damages sought by Anthem			$ 13,000,000,000
Express Scripts Litigation with Anthem | Judicial Ruling | Pricing Concessions After Remaining Term of Agreement
Commitments And Contingencies [Line Items]
Damages sought by Anthem			1,800,000,000
Express Scripts Litigation with Anthem | Pending Litigation | Damages for Service Issues
Commitments And Contingencies [Line Items]
Damages sought by Anthem			$ 150,000,000
Certain other guarantees, indemnification obligations in connection with acquisition and disposition transactions
Commitments And Contingencies [Line Items]
Liability for guarantees	0			0
Retiree and Life Insurance Benefits | Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure	430,000,000			430,000,000
Assets maintained by employers (minimum)				430,000,000
Liability for guarantees	$ 0			$ 0

Segment Information - Summary o

Segment Information - Summary of Special Items (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
After-tax
Integration and transaction-related costs (Selling, general and administrative expenses)	$ 37		$ 22
Debt extinguishment costs	0		101
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	0		(21)
Charge for organizational efficiency plan (Selling, general and administrative expenses)		$ 119
Total impact from special items	37		102
Before-tax
Integration and transaction-related costs (Selling, general and administrative expenses)	52		29
Debt extinguishment costs	0		131
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	0		(27)
Restructuring Charges		$ 168
Total impact from special items	$ 52		$ 133

Segment Information - Summarize

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Segment Reporting Information [Line Items]
Revenues from customers	$ 43,591		$ 40,580
Net investment income	414		391
TOTAL REVENUES	44,005		40,971
Net realized investment results from certain equity method investments	103		14
Adjusted revenues	44,108		40,985
Depreciation and amortization	717		715
Income before income taxes	1,549		1,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(17)		(12)
Net realized investment (gains) losses	422		13
Amortization of acquired intangible assets	458		495
Special items
Integration and transaction-related costs	52		29
Debt extinguishment costs	0		131
(Benefits) charges associated with litigation matters	0		(27)
Charge for organizational efficiency plan		$ 168
Pre-tax adjusted income (loss) from operations	2,464		2,142
Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	32,289		29,419
Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	10,461		10,285
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	841		876
Operating Segments | Evernorth
Segment Reporting Information [Line Items]
Net investment income	10		3
TOTAL REVENUES	33,586		30,620
Net realized investment results from certain equity method investments	0		0
Adjusted revenues	33,586		30,620
Income before income taxes	870		749
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(11)		(5)
Net realized investment (gains) losses	0		2
Amortization of acquired intangible assets	443		477
Special items
Integration and transaction-related costs	0		0
Debt extinguishment costs			0
(Benefits) charges associated with litigation matters			0
Pre-tax adjusted income (loss) from operations	1,302		1,223
Operating Segments | Cigna Healthcare
Segment Reporting Information [Line Items]
Net investment income	266		259
TOTAL REVENUES	11,289		11,053
Net realized investment results from certain equity method investments	103		14
Adjusted revenues	11,392		11,067
Income before income taxes	859		1,045
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(1)		(1)
Net realized investment (gains) losses	406		(16)
Amortization of acquired intangible assets	15		14
Special items
Integration and transaction-related costs	0		0
Debt extinguishment costs			0
(Benefits) charges associated with litigation matters			0
Pre-tax adjusted income (loss) from operations	1,279		1,042
Operating Segments | Other Operations
Segment Reporting Information [Line Items]
Net investment income	138		129
TOTAL REVENUES	979		1,005
Net realized investment results from certain equity method investments	0		0
Adjusted revenues	979		1,005
Income before income taxes	215		206
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(5)		(6)
Net realized investment (gains) losses	16		27
Amortization of acquired intangible assets	0		4
Special items
Integration and transaction-related costs	0		0
Debt extinguishment costs			0
(Benefits) charges associated with litigation matters			0
Pre-tax adjusted income (loss) from operations	226		231
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net investment income	0		0
TOTAL REVENUES	(1,849)		(1,707)
Net realized investment results from certain equity method investments	0		0
Adjusted revenues	(1,849)		(1,707)
Income before income taxes	(395)		(487)
Special items
Pre-tax adjusted income (loss) from operations	(343)		(354)
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	0		0
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	0		0
Net realized investment (gains) losses	0		0
Amortization of acquired intangible assets	0		0
Special items
Integration and transaction-related costs	52		29
Debt extinguishment costs			131
(Benefits) charges associated with litigation matters			(27)
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(1,849)		(1,707)
Intersegment Eliminations | Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	(1,287)		(1,198)
Intersegment Eliminations | Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	(562)		(509)
Intersegment Eliminations | Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ 0		$ 0

Segment Information - Revenue f

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from External Customer [Line Items]
Premiums	$ 10,356	$ 10,214
Total revenues from external customers	43,591	40,580
Intersegment Eliminations
Revenue from External Customer [Line Items]
Premiums	(2)	(1)
Total revenues from external customers	(1,849)	(1,707)
Operating Segments | International businesses held for sale
Revenue from External Customer [Line Items]
Premiums	763	809
Operating Segments | Other
Revenue from External Customer [Line Items]
Premiums	69	58
Evernorth
Revenue from External Customer [Line Items]
Total revenues from external customers	32,289	29,419
Evernorth | Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(1,287)	(1,198)
Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	10,461	10,285
Cigna Healthcare | Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(562)	(509)
Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	841	876
Other Operations | Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	0	0
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenues	30,697	28,025
Pharmacy revenues | Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(1,245)	(1,275)
Network revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	15,531	15,138
Home delivery and specialty revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	14,699	12,774
Other | Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,712	1,388
Cigna Healthcare | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	9,526	9,348
Insured | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	3,720	3,523
Stop loss | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,325	1,194
Other | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	360	310
Medicare Advantage | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	2,078	2,092
Medicare Part D | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	401	450
Other | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	940	1,138
International Health | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	702	641
Total fees and other revenues
Revenue from External Customer [Line Items]
Revenues	2,538	2,341
Total fees and other revenues | Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(602)	(431)
Fees | Evernorth | Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,624	1,314
Fees | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,496	1,434
Fees | Other Operations | Operating Segments
Revenue from External Customer [Line Items]
Revenues	5	5
Other revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	$ 15	$ 19

Segment Information - Narrative

Segment Information - Narrative (Details) - USD ($) $ in Billions	Mar. 31, 2022	Dec. 31, 2021
Pharmacy Benefits Management Services | Performance Guarantee
Loss Contingencies [Line Items]
Performance guarantee liability	$ 1.3	$ 1.1